WO2012170377A1 - Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides - Google Patents

Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Download PDF

Info

Publication number
WO2012170377A1
WO2012170377A1 PCT/US2012/040833 US2012040833W WO2012170377A1 WO 2012170377 A1 WO2012170377 A1 WO 2012170377A1 US 2012040833 W US2012040833 W US 2012040833W WO 2012170377 A1 WO2012170377 A1 WO 2012170377A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
linear
branched
ring
substituted
Prior art date
Application number
PCT/US2012/040833
Other languages
French (fr)
Inventor
Christopher M. LANTHIER
Boris Gorin
Jan Oudenes
Craig Edward DIXON
Alan Quigbo LU
James Densmore Copp
John Michael Janusz
Original Assignee
Akebia Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013158640/04A priority Critical patent/RU2602083C2/en
Priority to KR1020147000297A priority patent/KR102000485B1/en
Priority to PL17191362T priority patent/PL3290404T3/en
Priority to KR1020197007630A priority patent/KR102059366B1/en
Priority to KR1020207029586A priority patent/KR102293016B1/en
Priority to CA2838194A priority patent/CA2838194C/en
Priority to CN201280038564.3A priority patent/CN103717575B/en
Priority to KR1020197037296A priority patent/KR102171315B1/en
Priority to EP19214405.3A priority patent/EP3683209B1/en
Priority to EP21206374.7A priority patent/EP4026829A1/en
Priority to PL19214405T priority patent/PL3683209T3/en
Priority to CN201610967348.7A priority patent/CN106518759B/en
Priority to ES12796374.2T priority patent/ES2559850T3/en
Priority to AU2012268426A priority patent/AU2012268426B2/en
Priority to SI201230432T priority patent/SI2718265T1/en
Priority to RS20160013A priority patent/RS54517B1/en
Priority to DK12796374.2T priority patent/DK2718265T3/en
Application filed by Akebia Therapeutics Inc. filed Critical Akebia Therapeutics Inc.
Priority to KR1020197007633A priority patent/KR102032864B1/en
Priority to NZ618570A priority patent/NZ618570B2/en
Priority to EP12796374.2A priority patent/EP2718265B1/en
Priority to PL12796374T priority patent/PL2718265T3/en
Priority to MX2013014228A priority patent/MX337216B/en
Priority to MX2015016579A priority patent/MX347709B/en
Priority to JP2014514536A priority patent/JP6290781B2/en
Priority to EP17191362.7A priority patent/EP3290404B1/en
Publication of WO2012170377A1 publication Critical patent/WO2012170377A1/en
Priority to IL229775A priority patent/IL229775A/en
Priority to HK14110125.1A priority patent/HK1196616A1/en
Priority to HRP20151416T priority patent/HRP20151416T1/en
Priority to SM201600013T priority patent/SMT201600013B/en
Priority to AU2017202414A priority patent/AU2017202414B2/en
Priority to AU2018250355A priority patent/AU2018250355B2/en
Priority to CY20201100087T priority patent/CY1122639T1/en
Priority to AU2020204528A priority patent/AU2020204528B2/en
Priority to CY20211101079T priority patent/CY1124874T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Definitions

  • Figure 1 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitors.
  • Figure 2 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitor ester prodrugs.
  • Figure 3 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitor amide prodrugs.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • a weight percent of a component is based on the total weight of the formulation or composition in which the component is included.
  • Admixture or “blend” is generally used herein means a physical combination of two or more different components.
  • hydrocarbyl stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional group, including inorganic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts.
  • organic hydrocarbyl Within the broad meaning of the term “hydrocarbyl” are the classes “acyclic hydrocarbyl” and “cyclic hydrocarbyl” which terms are used to divide hydrocarbyl units into cyclic and non-cyclic classes.
  • cyclic hydrocarbyl units can comprise only carbon atoms in the ring (i.e., carbocyclic and aryl rings) or these units can comprise one or more heteroatoms in the ring (i.e., heterocyclic and heteroaryl rings).
  • Carbocyclic rings the lowest number of carbon atoms in a ring is 3 carbon atoms;
  • cyclopropyl For "aryl” rings the lowest number of carbon atoms in a ring are 6 carbon atoms; phenyl. For “heterocyclic” rings the lowest number of carbon atoms in a ring is 1 carbon atom; diazirinyl, a Ci heterocyclic ring. Ethylene oxide comprises 2 carbon atoms and is a C 2 heterocyclic ring. For “heteroaryl” rings the lowest number of carbon atoms in a ring is 1 carbon atom; 1,2,3,4-tetrazolyl, a Ci heteroaryl ring.
  • heterocycle and “heterocyclic ring” can also include “heteroaryl rings.”
  • heteroaryl rings The following is a non-limiting description of the units encompassed by the terms “acyclic hydrocarbyl” and “cyclic hydrocarbyl” as used herein.
  • substituted and unsubstituted acyclic hydrocarbyl encompasses 3 categories of units:
  • linear or branched alkyl non-limiting examples of which include, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), z ' so-propyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), z ' so-butyl (C 4 ), tert- butyl (C 4 ), and the like; substituted linear or branched alkyl, non-limiting examples of which includes, hydroxymethyl (Ci), chloromethyl (Ci), trifluoromethyl (Ci), aminomethyl (Ci), 1-chloroethyl (C 2 ), 2 -hydroxy ethyl (C 2 ), 1,2-difluoroethyl (C 2 ), 3-carboxypropyl (C 3 ), and the like.
  • linear or branched alkenyl non-limiting examples of which include, ethenyl (C 2 ), 3- propenyl (C 3 ), 1-propenyl (also 2-methylethenyl) (C 3 ), isopropenyl (also 2- methylethen-2-yl) (C3), buten-4-yl (C 4 ), and the like; substituted linear or branched alkenyl, non-limiting examples of which include, 2-chloroethenyl (also 2- chlorovinyl) (C 2 ), 4-hydroxybuten-l-yl (C 4 ), 7-hydroxy-7-methyloct-4-en-2-yl (C 9 ), 7-hydroxy-7-methyloct-3,5-dien-2-yl (C 9 ), and the like.
  • substituted linear or branched alkenyl non-limiting examples of which include, 2-chloroethenyl (also 2- chlorovinyl) (C 2 ), 4-hydroxybuten-l-y
  • linear or branched alkynyl non-limiting examples of which include, ethynyl (C 2 ), prop-2-ynyl (also propargyl) (C 3 ), propyn-l-yl (C 3 ), and 2-methyl-hex-4-yn-l-yl (C 7 ); substituted linear or branched alkynyl, non-limiting examples of which include, 5-hydroxy-5-methylhex-3-ynyl (C 7 ), 6-hydroxy-6-methylhept-3-yn-2-yl (Cs), 5-hydroxy-5-ethylhept-3-ynyl (C 9 ), and the like.
  • substituted and unsubstituted cyclic hydrocarbyl encompasses 5 categories of units:
  • carrier is defined herein as "encompassing rings comprising from 3 to 20 carbon atoms, in one embodiment from 3 to 10 carbon atoms, in another embodiment from 3 to 7 carbon atoms, in a still further embodiment 5 or 6 carbon atoms, wherein the atoms which comprise said rings are limited to carbon atoms, and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms.”
  • substituted and unsubstituted carbocyclic rings which encompass the following categories of units:
  • carbocyclic rings having a single substituted or unsubstituted hydrocarbon ring non-limiting examples of which include, cyclopropyl (C 3 ), 2-methyl- cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), 2,3-dihydroxycyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C5), cyclopentenyl (C5), cyclopentadienyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cycloheptyl (C 7 ), cyclooctanyl (C 8 ), 2,5- dimethylcyclopentyl (C5), 3,5-dichlorocyclohexyl (Ce), 4-hydroxycyclohexyl (Ce), and 3,3,5-trimethylcyclohex- l-yl (Ce).
  • carbocyclic rings having two or more substituted or unsubstituted fused hydrocarbon rings non-limiting examples of which include, octahydropentalenyl (C 8 ), octahydro- lH-indenyl (C 9 ), 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl (C 9 ), decahydroazulenyl (C 10 ).
  • bicyclo[2.2.1]heptanyl bicyclo[3.1.1 ]heptanyl, l,3-dimethyl[2.2.1 ]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
  • aryl is defined herein as "units encompassing at least one phenyl or naphthyl ring and wherein there are no heteroaryl or heterocyclic rings fused to the phenyl or naphthyl ring and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms.”
  • substituted and unsubstituted aryl rings which encompass the following categories of units:
  • C 6 or Cio substituted or unsubstituted aryl rings phenyl and naphthyl rings whether substituted or unsubstituted, non-limiting examples of which include, phenyl (Ce), naphthylen- l-yl (Cio), naphthylen-2-yl (Cio), 4-fluorophenyl (Ce), 2- hydroxyphenyl (Ce), 3-methylphenyl (Ce), 2-amino-4-fluorophenyl (Ce), 2-(N,N- diethylamino)phenyl (C 6 ), 2-cyanophenyl (C 6 ), 2,6-di-tert-butylphenyl (C 6 ), 3- methoxyphenyl (Ce), 8-hydroxynaphthylen-2-yl (Cio), 4,5-dimethoxynaphthylen-l- yl (Cio), and 6-cyano-nap
  • heterocyclic and/or “heterocycle” are defined herein as "units comprising one or more rings having from 3 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further the ring which contains the heteroatom is also not an aromatic ring.”
  • N nitrogen
  • O oxygen
  • S sulfur
  • Substituted and unsubstituted heterocyclic rings which encompass the following categories of units:
  • heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl (Ci), aziridinyl (C2), urazolyl (C2), azetidinyl (C 3 ), pyrazolidinyl (C 3 ), imidazolidinyl (C 3 ), oxazolidinyl (C 3 ), isoxazolinyl (C 3 ), thiazolidinyl (C 3 ), isothiazolinyl (C 3 ), oxathiazolidinonyl (C 3 ), oxazolidinonyl (C 3 ), hydantoinyl (C 3 ), tetrahydrofuranyl (C 4 ), pyrrolidinyl (C 4 ), morpholinyl (C 4 ), piperazinyl (C 4 ), piperidinyl (C 4 ), dihydropyranyl (C5)
  • heteroaryl is defined herein as "encompassing one or more rings comprising from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further at least one of the rings which comprises a heteroatom is an aromatic ring.”
  • Heteroaryl rings can comprise from 1 to 19 carbon atoms, in another embodiment heteroaryl rings can comprise from 1 to 9 carbon atoms.
  • substituted and unsubstituted heterocyclic rings which encompass the following categories of units:
  • heteroaryl rings containing a single ring non-limiting examples of which include, 1,2,3,4-tetrazolyl (CO, [l,2,3]triazolyl (C 2 ), [l,2,4]triazolyl (C 2 ), triazinyl (C 3 ), thiazolyl (C 3 ), IH-imidazolyl (C 3 ), oxazolyl (C 3 ), isoxazolyl (C 3 ), isothiazolyl (C 3 ), furanyl (C 4 ), thiophenyl (C 4 ), pyrimidinyl (C 4 ), 2-phenylpyrimidinyl (C 4 ), pyridinyl (C5), 3-methylpyridinyl (C5), and 4-dimethylaminopyridinyl (C5) ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7H-purinyl (
  • Ci-Ce tethered cyclic hydrocarbyl units (whether carbocyclic units, Ce or C 10 aryl units, heterocyclic units, or heteroaryl units) which connected to another moiety, unit, or core of the molecule by way of a Ci-Ce alkylene unit.
  • tethered cyclic hydrocarbyl units include benzyl Ci-(C 6 ) having the formula:
  • R a is optionally one or more independently chosen substitutions for hydrogen.
  • R a is optionally one or more independently chosen substitutions for hydrogen.
  • Further examples include other aryl units, inter alia, (2- hydroxyphenyl)hexyl C6-(Ce); naphthalen-2-ylmethyl Ci-(Cio), 4-fluorobenzyl Ci- (C 6 ), 2-(3-hydroxyphenyl)ethyl C 2 -(Ce), as well as substituted and unsubstituted C 3 - C1 0 alkylenecarbocyclic units, for example, cyclopropylmethyl Ci-(C 3 ),
  • cyclopentylethyl C 2 -(Cs), cyclohexylmethyl C ⁇ -(C£); Included within this category are substituted and unsubstituted C1-C1 0 alkylene-heteroaryl units, for example a 2- picolyl Ci-(C 6 ) unit having the formula:
  • C1-C12 tethered cyclic hydrocarbyl units include C1-C1 0 alkyleneheterocyclic units and alkylene-heteroaryl units, non-limiting examples of which include, aziridinylmethyl Ci-(C2) and oxazol- 2-ylmethyl d-(C 3 ).
  • carbocyclic rings are from C3 to C2 0 ; aryl rings are Ce or Cio; heterocyclic rings are from Ci to C9; and heteroaryl rings are from Ci to C 9 .
  • fused ring units as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be characterized and referred to herein as being encompassed by the cyclic family corresponding to the heteroatom containing ring, although the artisan may have alternative characterizations.
  • 1,2,3,4- tetrahydroquinoline having the formula:
  • heteroaryl unit is, for the purposes of the present disclosure, is defined as a heteroaryl unit.
  • a fused ring unit contains heteroatoms in both a non-aromatic ring (heterocyclic ring) and an aryl ring (heteroaryl ring)
  • the aryl ring will predominate and determine the type of category to which the ring is assigned herein for the purposes of describing the invention.
  • l,2,3,4-tetrahydro-[l,8]naphthpyridine having the formula:
  • substituted is used throughout the specification.
  • substituted unit or moiety is a hydrocarbyl unit or moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below.”
  • the units, when substituting for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time.
  • these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety, or unit.
  • a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like.
  • a two hydrogen atom replacement includes carbonyl, oximino, and the like.
  • a two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like.
  • Three hydrogen replacement includes cyano, and the like.
  • substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain; can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as "substituted" any number of the hydrogen atoms may be replaced.
  • 4-hydroxyphenyl is a "substituted aromatic carbocyclic ring (aryl ring)"
  • ( ,N-dimethyl-5-amino)octanyl is a " substituted Cs linear alkyl unit
  • 3-guanidinopropyl is a "substituted C 3 linear alkyl unit”
  • 2-carboxypyridinyl is a "substituted heteroaryl unit.”
  • substituted or unsubstituted Ce or C10 aryl for example, phenyl, naphthyl (also referred to herein as naphthylen- 1 -yl (C 10 ) or naphthylen-2-yl (C 10 )); iii) substituted or unsubstituted C7 or Cn alkylenearyl; for example, benzyl, 2- phenylethyl, naphthylen-2-ylmethyl;
  • -(CR 102a R 102b ) a OR 101 for example, -OH, -CH 2 OH, -OCH 3 , -CH 2 OCH 3 , -OCH 2 CH 3 , -CH 2 OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , and -CH 2 OCH 2 CH 2 CH 3 ;
  • -(CR 102a R 102b ) a C(O)R 101 for example, -COCH3, -CH 2 COCH 3 ,
  • each R 101 is independently hydrogen, substituted or unsubstituted C 1-C6 linear, C 3 - C 6 branched, or C 3 -C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R 101 units can be taken together to form a ring comprising 3-7 atoms;
  • R 102a and 102b are each independently hydrogen or C1-C4 linear or C 3 -C 4 branched alkyl; the index "a" is from 0 to 4.
  • substitutions for hydrogen defined herein above for example, substituted Ci-Ci 2 linear, C 3 -Ci 2 branched, or C 3 -Ci 2 cyclic alkyl, alkenyl, and alkynyl, substituted Ce or C10 aryl, substituted C 7 or Cn alkylenearyl, substituted C1-C9 heterocyclic rings, substituted Ci- C9 heteroaryl rings, and R 101 , can be optionally substituted by one or more of the following substitutions for hydrogen:
  • each R 201 is independently hydrogen, C1-C6 linear, C 3 -C6 branched, or C 3 -C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R 201 units can be taken together to form a ring comprising 3-7 atoms; 202a and R 202b are each independently hydrogen or Ci- C 4 linear or C 3 -C 4 branched alkyl; the index "b" is from 0 to 4.
  • composition of matter stand equally well for each other and are used interchangeably throughout the specification.
  • the disclosed compounds include all enantiomeric forms, diastereomeric forms, salts, and the like.
  • the compounds disclosed herein include all salt forms, for example, salts of both basic groups, inter alia, amines, as well as salts of acidic groups, inter alia, carboxylic acids.
  • anions that can form salts with protonated basic groups: chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, citrate, and the like.
  • cations that can form salts of acidic groups: ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, lysine, tromethamine, meglumine and the like.
  • L is a linking group defined herein, have been found to exhibit prolyl hydroxylase inhibition (antagonism). Compounds of this formula have also been found to stabilize hypoxia inducible factor-2 alpha (HIF-2a). It has also been found that esters and amides having the formula:
  • esters and amides are referred to herein as "prodrugs.”
  • R units have the formula:
  • X is chosen from:
  • R 3 is C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C 3 -C12 cyclic alkenyl; or C2-C12 linear, C 3 -C12 branched or C 3 -C12 cyclic alkynyl, or benzyl.
  • R 4 and R 5 are each independently hydrogen, C1-C12 linear, C 3 -C12 branched or C 3 - C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C 3 -C12 branched or C 3 -C12 cyclic alkynyl; benzyl; or R 4 and R 5 can be taken together with the nitrogen atom to form a 3 to 10 member ring, wherein the ring can optionally contain one or more heteroatoms chosen from oxygen (O), nitrogen (N), or sulfur (S).
  • M 1 represents a cation as further described herein below.
  • Non-limiting examples of this embodiment includes compounds having the formula:
  • X is hydroxyl, -OH.
  • X is -OR 3 .
  • R 3 is Ci-Ce linear alkyl, for example, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (C5), and n-hexyl (Ce).
  • Non-limiting examples include the methyl ester, the ethyl ester, the n-propyl ester, and the like.
  • R 3 is C3-C6 branched alkyl non-limiting examples of which include z ' so-propyl (C 3 ), sec-butyl (C 4 ), iso-butyl (C 4 ), tert-butyl (C 4 ), 1 -methylbutyl (C 5 ), 2-methylbutyl (C 5 ), 3-methylbutyl (C 5 ), and 4- methylpentyl (Ce).
  • a further embodiment of this aspect relates to X units wherein R 3 is C3-C6 cyclic alkyl, for example, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C5), and cyclohexyl (Ce).
  • R 3 is C3-C6 cyclic alkyl, for example, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C5), and cyclohexyl (Ce).
  • X is -NR 4 R 5 .
  • One embodiment of this aspect relates to X units wherein R 4 and R 5 are both hydrogen; -NH 2 .
  • a further embodiment of this aspect relates to X units wherein R 4 and R 5 are independently chosen from hydrogen, C 1 -C 4 linear alkyl, C3-C4 branched alkyl, or C3-C4 cyclic alkyl, for example, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), z ' so-butyl (C 4 ), and tert-butyl (C 4 ).
  • R 4 and R 5 are independently chosen from hydrogen, C 1 -C 4 linear alkyl, C3-C4 branched alkyl, or C3-C4 cyclic alkyl, for example, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), iso-propyl (C 3 ), n-butyl (C 4 ), sec-but
  • Non-limiting examples of this embodiment include -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NHC 2 H 5 , -N(C 2 H 5 ) 2 , and - N(CH 3 )(C 2 H 5 ).
  • L is a linking unit having the formula -(CR 7a R 7b ) n - wherein R 7a and R 7b can be independently chosen from hydrogen, Ci-Ce linear, C3-C6 branched or C3-C6 cyclic alkyl.
  • the index n is an integer from 1 to 4.
  • R 7a and R 7b are both hydrogen and the index n is an integer from 1 to 4, i.e., -CH 2 - (methylene), -CH 2 CH 2 - (ethylene), -CH 2 CH 2 CH 2 - (propylene), and -CH 2 CH 2 CH 2 CH 2 - (butylene).
  • n is an integer from 1 to 4, i.e., -CH 2 - (methylene), -CH 2 CH 2 - (ethylene), -CH 2 CH 2 CH 2 - (propylene), and -CH 2 CH 2 CH 2 CH 2 - (butylene).
  • a further aspect of L units relates to L units wherein R 7a and R 7b are independently chosen from hydrogen, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), and z ' so-propyl (C 3 ) and the index n is an integer from 1 to 4.
  • R 7a is hydrogen and R 7b is chosen from methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), and iso- propyl (C 3 ), and the index n is an integer from 1 or 3.
  • Non-limiting examples of this embodiment includes -CH(CH 3 )-, -CH 2 CH(CH 3 )-, -CH(CH 3 )CH 2 - -CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 - and -CH 2 CH 2 CH(CH 3 )-.
  • L units relate to L units wherein R 7a and R 7b are
  • n is an integer from 1 to 4.
  • a non-limiting example of this aspect has the formula -C(CH 3 ) 2 -.
  • L units can be derived from the reaction of an amino acid with a 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine as described herein below in the disclosure of process step D.
  • R 7b is hydrogen and R 7a is chosen from hydrogen, methyl, z ' sopropyl, iso- butyl, sec-butyl, hydroxymethyl, 1 -hydroxy ethyl, thiomethyl, 2-(methylthio)ethyl, benzyl, (4-hydroxyphenyl)methyl, indol-3-ylmethyl, imidazol-4-ylmethyl, 3-gunidinylpropyl, 4- aminobutyl, carboxymethyl, 2-carboxyethyl, acetamide, or R 8 and R 7a can be taken together to form a pyrrolidinyl ring, for example, when proline is reacted with the 5-aryl or 5- heteroaryl
  • n can be any integer from 1 to 4, for example n can equal 1, n can equal 2, n can equal 3, and n can equal 4.
  • R 8 is hydrogen, methyl (CO or ethyl (C 2 ). In one aspect R 8 is hydrogen. In a further aspect R 8 is methyl (CO- In another aspect R 8 is ethyl (C 2 ).
  • R 1 units are chosen from:
  • substitutions for a hydrogen atom on R 1 units, or alternatively an R 10 unit when R 1 is represented by an A ring include:
  • -(CR 102a R 102b ) a OR 101 for example, -OH, -CH 2 OH, -OCH 3 , -CH 2 OCH 3 , -OCH2CH3, -CH2OCH2CH3, -OCH2CH2CH3, and -CH2OCH2CH2CH3; vii) -(CR 102a R 102b ) a C(O)R 101 ; for example, -COCH 3 , -CH 2 COCH 3 ,
  • two substitutions for hydrogen can be taken together to form a substituted or unsubstituted C 2 -Cs heterocyclic ring, wherein the ring substitution can be one or more of the substitutions defined in (i) to (xix) herein above and the ring can comprise one or more heteroatoms chosen from oxygen (O) sulfur (S), or nitrogen (N);
  • each R 101 is independently hydrogen, substituted or unsubstituted Ci-Ce linear, C 3 - Ce branched, or C 3 -C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R 101 units can be taken together to form a ring comprising 3-7 atoms; 102a and R 102b are each independently hydrogen or C1-C4 linear or C 3 -C 4 branched alkyl; the index "a" is from 0 to 4.
  • a ring represents R 1 units wherein R 1 can be:
  • R 1 relates to substituted or unsubstituted Ce aryl, i.e., substituted or unsubstituted phenyl.
  • a first embodiment of this aspect relates to R 1 equal to phenyl, for example, compounds having the formula:
  • R 1 A further aspect of R 1 relates to R 1 units that are substituted phenyl having the formula:
  • R represents from 1 to 5 independently chosen substitutions for hydrogen; or two R 10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted Ce aryl ring (phenyl), a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
  • R 1 units relates to compounds comprising substitutions on R 1 of one or more units independently chosen from:
  • halogen -F, -CI, -Br, and -I.
  • R 1 units 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5- difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4- dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3,5-dichlorophenyl,
  • a further iteration relates to compounds comprising one or more R units that are C1-C4 linear, C3-C4 branched or C3-C4 cyclic alkyl, thereby forming the following non- limiting examples of R 1 units: 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,3- dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4- dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5- trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3- diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethy
  • Another iteration relates to compounds comprising one or more R 10 units that are
  • R 1 units 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3- dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4- dimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6- trimethoxyphenyl, 2,4,5 -trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-ethoxyphenyl, 3- ethoxyphenyl, 4-ethoxyphenyl, 2,3-diethoxyphenyl, 2,4-diethoxyphenyl, 2,5- diethoxyphenyl, 2,6-diethoxyphenyl, 3,4-diethoxyphen
  • a yet still further iteration relates to compounds comprising one or more R 10 units that comprise at least one of each substitution chosen from C1-C4 linear or halogen, thereby forming the following non-limiting examples of R 1 units: 2-chloro-3-methylphenyl, 2- chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-6-methylphenyl, 3-chloro-2- methylphenyl, 3-chloro-4-methylphenyl, 3-chloro-5-methylphenyl, 3-chloro-6-methyl- phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluoro-5-methylphenyl, 2- fluoro-6-methylphenyl, 3-fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl, 3-fluoro-5- methylphenyl, and 3-fluoro-6-methylphenyl.
  • R 1 units relates to compounds comprising one or more R 10 units independently chosen from:
  • R 1 units that are -(CH2) a C , wherein the index a is 0 or 1 , thereby forming the following non- limiting examples of R 1 units: 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2- (cyanomethyl)phenyl, 3-(cyanomethyl)phenyl, 4-(cyanomethyl)phenyl, 2,3-dicyanophenyl, 3,4-dicyanophenyl, and 3,5-dicyanophenyl.
  • R 10 units that are -(CH 2 ) a N0 2 , wherein the index a is 0 or 1, thereby forming the following non-limiting examples of R 1 units: 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2- (nitromethyl)phenyl, 3-(nitromethyl)phenyl, 4-(nitromethyl)phenyl, 2,3-dinitrophenyl, 3,4- dinitrophenyl, and 3,5-dinitrophenyl.
  • R 1 units that are -(CR 102a R 102b ) a N(R 101 ) 2 , wherein the index a is 0 or 1, thereby forming the following non-limiting examples of R 1 units: 2-aminophenyl, 3-aminophenyl, 4- aminophenyl, 2,3-diaminophenyl, 3,4-diaminophenyl, 3,5-diaminophenyl, 2- methylaminophenyl, 3-methylaminophenyl, 4-methylaminophenyl, 2,3- (dimethylamino)phenyl, 3,4-(dimethylamino)phenyl, 3,5-(dimethylamino)phenyl, 2,3,4- triaminophenyl, 2,3,5-triaminophenyl, 2,3,6-triaminophenyl, 2,4,5-triaminophenyl, 2,4,6- triaminophen
  • R 10 units that are -(CR 102a R 102b ) a C(O)N(R 101 ) 2 , wherein R 101 is chosen from hydrogen, d- Ce linear, C3-C6 branched alkyl or C3-C6 cyclic alkyl, and the index a is 0 or 1 , thereby forming the following non- limiting examples of R 1 units: -C(0)NH 2 , -C(0)NHCH 3 , -CH 2 C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -CH 2 C(0)N(CH 3 ) 2 , -C(0)NHCH 2 CH 3 ,
  • R 10 units that are -(CR 102a R 102b ) a C(O)N(R 101 ) 2 , wherein two R 101 units are taken together to form a ring having from 3 to 7 atoms and the index a is 0 or 1, thereby forming R 1 units having, for example, the formulae:
  • R 10 units that are -(CR 102a R 102b ) a N(R 101 )C(O) 2 R 101 ; wherein R 101 is chosen from hydrogen, C1-C6 linear, C 3 -C6 branched alkyl or C 3 -C6 cyclic alkyl, and the index a is 0 or 1 , thereby forming the following non-limiting examples of R 1 units: -NHC(0)CH 3 ,
  • R 1 relates to R 1 units that are substituted or unsubstituted Ci- heteroaryl.
  • R 1 equal to C 1 -C9 heteroaryl, for example, compounds having the formula:
  • ring A represent a C 1 -C9 heteroaryl unit non-limiting examples of which include: 1,2,3,4-tetrazolyl (CO, [l,2,3]triazolyl (C 2 ), [l,2,4]triazolyl (C 2 ), [l,2,4]oxadiazolyl (C 2 ), [l,3,4]oxadiazolyl (C 2 ), [l,2,4]thiadiazolyl (C 2 ), [l,3,4]thiadiazolyl (C 2 ), isothiazolyl (C 3 ), thiazolyl (C 3 ), imidazolyl (C 3 ), oxazolyl (C 3 ), isoxazolyl (C 3 ), pyrazolyl (C 3 ), pyrrolyl (C 4 ), furanyl (C 4 ), thiophenyl (C 4 ), triazinyl (C 3 ), pyrimidinyl (C 4 ), pyrazinyl (
  • the C 1 -C9 heteroaryl unit can be bonded to the core pyridine ring at any suitable position, non-limiting examples of which include:
  • R 1 units equal to substituted C1-C9 heteroaryl, for example, compounds having the formula:
  • ring A represent a C 1 -C9 heteroaryl unit non-limiting examples of which include: 1,2,3 ,4-tetrazolyl (CO, [l,2,3]triazolyl (C 2 ), [l,2,4]triazolyl (C 2 ), [l,2,4]oxadiazolyl (C 2 ), [l,3,4]oxadiazolyl (C 2 ), [l,2,4]thiadiazolyl (C 2 ), [l,3,4]thiadiazolyl (C 2 ), isothiazolyl (C 3 ), thiazolyl (C 3 ), imidazolyl (C 3 ), oxazolyl (C 3 ), isoxazolyl (C 3 ), pyrazolyl (C 3 ), pyrrolyl (C 4 ), furanyl (C 4 ), thiophenyl (C 4 ), triazinyl (C 3 ), pyrimidinyl (C 4 ), pyraziny
  • Non-limiting examples of substitutions for a hydrogen atom on R 1 C 1 -C 9 heteroaryl units include:
  • -(CR 102a R 102b ) a OR 101 for example, -OH, -CH 2 OH, -OCH 3 , -CH 2 OCH 3 , -OCH 2 CH 3 , -CH 2 OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , and -CH 2 OCH 2 CH 2 CH 3 ;
  • -(CR 102a R 102b ) a C(O)R 101 for example, -COCH 3 , -CH 2 COCH 3 ,
  • each R 101 is independently hydrogen, substituted or unsubstituted C 1 -C6 linear, C 3 - Ce branched, or C 3 -C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R 101 units can be taken together to form a ring comprising 3-7 atoms; 102a and R 102b are each independently hydrogen or C 1 -C4 linear or C 3 -C 4 branched alkyl; the index "a" is from 0 to 4.
  • Non-limiting examples of substituted C5-C9 R 1 heteroaryl units include 2- methylthiazol-4-yl, 2-ethylthiazol-4-yl, 2-(n-propyl)thiazol-4-yl, 2-(3 ⁇ 4o-propyl)thiazol-4-yl, 4,5-dimethylthiazol-2-yl, 4-ethyl-5-methylthiazol-2-yl, 4-methyl-5-ethylthiazol-2-yl, 4,5- diethylthiazol-2-yl, 3-methyl-l ,2,4-oxadiazol-5-yl, 4,5-dimethylimidazol-2-yl, 4-ethyl-5- methylimidazol-2-yl, 4-methyl-5-ethylimidazol-2-yl, 4,5-diethylimidazol-2-yl, 2,5- dimethylthiazol-4-yl, 2,4-dimethylthiazol-5-yl, 3 -methyl
  • Non-limiting examples of substituted C 2 -C 4 5-member heteroaryl rings include:
  • R 1 units relate to rings comprising two R 10 substitutions for hydrogen that are taken together to form a substituted or unsubstituted C2-C8 heterocyclic ring.
  • One embodiment of this aspect relates to R 1 units wherein two R 10 units are taken together to form a substituted or unsubstituted C7-C9 heterocyclic R 1 ring system wherein the heterocyclic ring formed by the two R 10 substitutions contains one or more nitrogen atoms.
  • No -limiting iterations of this embodiment include R 1 units having the formulae:
  • R 1 units wherein two R 10 units are taken together to form a substituted or unsubstituted C7-C9 heterocyclic R 1 ring system wherein the heterocyclic ring formed by the two R 10 substitutions contains one or more oxygen atoms.
  • Non-limiting iterations of this embodiment include R 1 units having the formulae:
  • R 2 units are chosen from C1-C12 linear alkyl or C3-C12 branched alkyl. In one embodiment R 2 can represent hydrogen. In another embodiment, R 2 is C1-C4 linear alkyl. Non-limiting examples include methyl, ethyl and n-propyl. In one example, R 2 is methyl. R 2 units relate to the alkoxide unit having the formula:
  • the alkoxide can be derived from any suitable source, i.e., sodium methoxide, lithium ethoxide, and the like which the formulator can choose.
  • a further aspect of the present disclosure relates to a process for preparing intermediates having the formula:
  • R x is the same as defined herein above.
  • This aspect also includes salts of acids, for example, compounds having the formula:
  • M is a salt forming cation and N represents the cationic charge on M and the number of corresponding anionic units of the disclosed intermediates.
  • the M units can comprise in one embodiment inorganic cations, inter alia, ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, and the like.
  • M units can comprise organic cation forming units, inter alia, lysine, ornithine, glycine, alanine, or other amino acids, basic organic compounds, inter alia, methylamine, dimethylamine, trimethylamine, and the like.
  • W is a salt forming anion and Y represents the anionic charge on W and the number of corresponding number of the disclosed intermediates in this salt form.
  • the W units can comprise in one embodiment inorganic anions, inter alia, chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, and the like.
  • W units can comprise organic anion forming units, inter alia, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, citrate, and the like.
  • the disclosed prolyl hydroxylase inhibitors can be isolated as a pharmaceutically acceptable salt having the formula:
  • M is a salt forming cation and N represents the cationic charge on M and the number of corresponding anionic units present in the salt.
  • One aspect of the disclosed salts relates to prolyl hydroxylase inhibitors in the of the mono-valent salt having the formula:
  • M represents an inorganic or organic cation.
  • monovalent cations include sodium, lithium, potassium, ammonium, silver, organic cations having the formula HN + R a R b R c wherein R a , R b and R c are each independently:
  • R a , R b and R c can be independently substituted by one or more units chosen from:
  • R a , R b and R c can contain one or more units capable of
  • R a , R b and R c are hydrogen or C1-C12 linear alkyl.
  • Non-limiting examples include methyl ammonium
  • R a , R b and R c are chosen from hydrogen, unsubstituted Ci-Ci 2 linear, C 3 -Ci 2 branched, or C 3 - Ci 2 cyclic alkyl or substituted Ci-Ci 2 linear, C 3 -Ci 2 branched, or C 3 -Ci 2 cyclic alkyl.
  • R a , R b and R c are chosen from hydrogen, unsubstituted Ci-Ci 2 linear, C 3 -Ci 2 branched, or C 3 - Ci 2 cyclic alkyl or substituted Ci-Ci 2 linear, C 3 -Ci 2 branched, or C 3 -Ci 2 cyclic alkyl.
  • Non-limiting examples include 2- hydroxyethyl ammonium (cation of monoethanolamine, cholinate) [HN + H 2 (CH 2 CH 2 OH)], methyl-2-hydroxyethyl ammonium [H 2 N + (CH 3 )(CH 2 CH 2 OH)], di(2 -hydroxyethyl) ammonium [H 2 N + (CH 2 CH 2 OH) 2 ], tri(2-hydroxyethyl) ammonium [HN + (CH 2 CH 2 OH) 3 ], and tris(hydroxymethyl)methyl ammonium (cation of tris(hydroxymethyl)aminomethane) [H 3 N + C[(CH 2 OH)] 3 ].
  • amino sugars having the formula H 2 N (CH 3 )[(CHOH) n CH 2 OH] wherein n is from 1 to 7.
  • amino sugars suitable for forming an organic cation is meglumine ( 1 -deoxy- 1 -methylamino-sorbitol).
  • a further iteration of this embodiment relates to cations formed from amino acids.
  • Non-limiting examples include lysine, ornithine, arginine, glutamine, and the like.
  • organic amines suitable for forming salts of the disclosed stabilizer include amines wherein one or more of R a , R b and R c are taken together to form a heterocyclic ring that can comprise from 3 to 20 atoms and optionally one or more heteroatoms chosen from nitrogen, oxygen and sulfur.
  • Non-limiting examples include piperazine, piperidine, morpholine, thiomorpholine, and the like.
  • Non-limiting examples of di-valent cations includes calcium magnesium, barium and the like.
  • the formulator can prepare an admixture comprising a plurality of final compounds in one step by the choice of reactants in the final process step as described herein.
  • the formulator can prepare an admixture comprising a plurality of final compounds in one step by the choice of reactants in the final process step as described herein.
  • two or more analogs can have approximately equal pharmacological activity, other properties such as bioavailability can be different.
  • Using the disclosed intermediates to form admixtures of final analogs can provide the formulator with a final composition which utilizes the disparate pharmacological activities of the molecules to provide for a constant level of a desired property.
  • one analog in the admixture can have immediate bioavailability while a second or third compound has a slower bioavailability which can provide a pharmacologically active composition that has a steady or near steady level of drug active in a user.
  • Disclosed herein is a process for preparing the herein above disclosed [(5-phenyl-3- hydroxypyridine-2-carbonyl)-amino]alkanoic acids and [(5-heteroaryl-3-hydroxypyridine- 2-carbonyl)-amino]alkanoic acids.
  • the 5-phenyl and 5-heteroaryl rings can be substituted by one or more independently chosen substitutions for hydrogen.
  • Step A relates to the condensation of an aryl or heteroaryl borate precursor, Al, and a 3,5-dihalo-2-cyanopyridine, A2, wherein each Z is independently chloro or bromo, to form a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine, A3.
  • the borate precursor, Al comprises ring A wherein ring A can be:
  • Y is OR 20 , wherein R 20 is hydrogen or C1-C 6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, or two OR 20 units can be taken together to form a 5-member to 7-member C3-C1 0 cyclic ester, for example, a cyclic ester having the formula:
  • borate precursor to phenyl boronic acid having the formula:
  • borate precursors relates to substituted boronic acids having the formula:
  • R represents from 1 to 5 substitutions as defined herein above.
  • Non-limiting examples of this aspect includes borate precursors having the formula:
  • the 3,5-dihalo-2-cyanopyridine, A2 is chosen from 3,5-dichloro-2-cyanopyridine, 3-chloro-5-bromo-2-cyanopyridine, 3,5-dibromo-2-cyanopyridine and 3-bromo-5-chloro-2- cyanopyridine.
  • Step A is conducted in the presence of a catalyst, for example, a Suzuki coupling catalyst.
  • the formulator can choose the catalyst and conditions that are compatible with the reagents, i.e., borate precursor and 3,5-dihalo-2-cyanopyridine.
  • the catalyst is [l,l '-bis(diphenyphosphino)ferrocene]dichloro- palladium(II) [PdCl 2 (dppf)].
  • catalysts include ortho-metalated catalysts with alkylphosphine ligands of the general formula [Pd(X)(K 2 N,C-C 6 H 4 CH 2 NMe 2 )(PR3)] wherein R is Cy, X is trifluoroacetate, trifluoromethanesufonyl, chloro, or iodo; PR 3 is PCy 2 (o-biphenyl), X is trifluoroacetate).
  • Non-limiting examples of this category include [ ⁇ Pd ⁇ -TFA)(K 2 N,C-
  • the catalyst can be preformed, for example, purchased from a chemical supplier or the catalyst can be generated in situ.
  • Step A wherein the catalyst is generated in situ includes the following procedure. Pd(OAc) 2 (1.5 mmol %), 3,3 '-dimethyl- l, (2,4-bismethylenemesitylene)(4,4,5,6-tetrahydropyrimidinium) chloride (1.5 mmol %), a borate precursor (1.5 mmol), a 3,5-dihalo-2-cyanopyridine (1.0 mmol), K 2 C0 3 (2 mmol), water (3 mL)-DMF (3 mL) are added to a small Schlenk tube and the mixture heated at 80 °C for 5 hours. At the conclusion of the reaction, the mixture is collected, removed by extraction with suitable solvent, and the desired product isolated by methods known to the artisan.
  • Step A is conducted in the presence of a base.
  • suitable bases that can be used in Step A includes LiOH, NaOH, KOH, Ca(OH) 2 , Li 2 C0 3 , Na 2 C0 3 , K 2 C0 3; and CaC0 3 .
  • the base is K 2 C0 3 .
  • the base is Na 2 C0 3 .
  • Step A can be optionally conducted in the presence of a solvent.
  • solvents include water, formic acid, acetic acid; alcohols, for example, methanol, ethanol, 2,2,2-trichlorethanol, propanol, isopropanol, butanol, tert-butanol, and the like; ketones, for example, acetone, methyl ethyl ketone, diethyl ketone, and the like; esters, for example, methyl acetate, ethyl acetate, methyl propionate, ethyl propionate, and the like; ethers, for example, diethyl ether, methyl tert-butyl ether, tetrahydrofuran, dimethoxyethane, bis(2-methoxyethyl) ether (diglyme), l,4-dioxane,and the like; alkanes, for example, pentane, isopentane, petroleum
  • the reaction can be conducted at any temperature sufficient to provide the desired products or desired products.
  • Step B relates to the conversion of a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine, A3, to a 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine, B.
  • intermediate A3 can be reacted with methoxide anion.
  • the methoxide anion can be generated in situ, for example, by the addition of an alkali metal to methanol. In one example, from 1 equivalent to 10 equivalents of sodium metal based upon the amount of A3 to be converted in Step B, is added to an excess of methanol. In another example, an alkali metal is added to an excess of methanol, the solvent removed, and the resulting sodium methoxide retained for use when, for example, Step B is conducted in a solvent other than methanol.
  • the intermediate A3 can be reacted with ethoxide anion generated from ethanol. In still another embodiment, the intermediate A3 can be reacted with isopropoxy anion generated from isopropanol.
  • step B can be conducted at any temperature sufficient to provide the desired products or desired products.
  • step B can be conducted in any solvent or mixtures of solvents that do not react with methoxide anion under the conditions chosen by the formulator.
  • Step C relates to the conversion of the 5-aryl or 5-heteroaryl-3-alkoxy-2- cyanopyridine formed in step B to form a 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine, C, (5-aryl or 5-heteroaryl-3-hydroxypicolinic acid).
  • This conversion can be conducted in the presence of any acid capable of hydrolysis of the cyano moiety to a carboxylic acid moiety and the methoxy moiety to a hydroxyl moiety.
  • 48% aqueous HBr can be used.
  • 37% aqueous HC1 can be used.
  • the compounds having formula C can be isolated as the free acid or as a salt, for example, as a compound having the formula:
  • the formulator can proceed to step D or retain the products of step C for use in preparing admixtures of prolyl hydroxylase inhibitors or for preparing prodrugs of prolyl hydroxylase inhibitors.
  • Step D relates to the reaction of the 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine formed in step C with a compound having formula D 1 , wherein X is chosen from -OH, -OR 3 , -NR 4 R 5 or -OM 1 as defined herein above, to form one of the following:
  • step D relates to formation of a prolyl hydroxylase inhibitor according to the following scheme:
  • R 7a , R 7b , R 8 and the index n are defined herein above.
  • step D relate to formation of a prolyl hydroxylase ester prodrug according to the following scheme:
  • R 3 , R 7a , R 7b , R 8 and the index n are defined herein above.
  • step D relate to formation of a prolyl hydroxylase amide prodrug according to the following scheme:
  • R 4 , R 5 , R 7a , R 7b , R 8 and the index n are defined herein above.
  • Step D relates to the coupling of a 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxy- pyridine, C, prepared in Step C with an amino acid, amino acid ester, or amino acid amide.
  • Any coupling reagent compatible with the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxy- pyridine, amino acid, amino acid ester, or amino acid amide can be used to prepare the desired prolyl hydroxylase inhibitors or prodrugs thereof.
  • Non-limiting examples of coupling reagents includes carbonyldiimidazole (CDI), dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), and ethyl-(N',N'-dimethylamino)propylcarbodiimide (EDC), (benzotriazol- 1 -yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol- l -yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 0-(benzotriazol-l -yl)-N,N,N'N'-tertaetyluronium hexafluorophosphate (HBTU), O- (benzotriazol- l-yl)-N,N,N'N'-tertamethyluronium tetrafluorobo
  • step D can be conducted with a suitable reagent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP).
  • a suitable reagent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP).
  • a further iteration of the reaction outlined in step D utilizes an in situ generated mixed anhydride of the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine, for example, reacting compound C with a mixed anhydride forming reagent.
  • a mixed anhydride forming reagent include isobutylchloro-formate (IBCF), ethylchoroformate, isopropylchloroformate, and the like.
  • Other coupling reagents include 2-chloro-3,6-dimethoxy-l,3,5-triazine, pivalolyl chloride and triphosgene.
  • acyl chlorides can be used to activate the carbonyl moiety of compound C for the coupling exemplified in step D.
  • pivaloyl chloride in THF are used to catalyze the coupling reaction.
  • An organic or inorganic base can be used for conducting step D.
  • suitable organic bases include diisopropylethylamine, and the like.
  • Step D can be conducted in one or more solvents.
  • solvents include dimethylformamide (DMF), diethylformamide (DEF), dimethylacetamide (DMA), diethylacetamide(DEA), dimethyl sulfoxide(DMSO), dioxane, and water.
  • a mixture of water and one or more polar organic solvents can be used, for example, DMF/water, DMSO/water, dioxane/water, DMF/dioxane/water, and the like.
  • the formulator can form a prodrug prior then further process the prodrug to the final prolyl hydroxylase inhibitor.
  • the intermediate C may comprise an R 10 unit that has a protecting group present, i.e., carbobenzyloxy, tert-butoxycarbonyl, and the like.
  • a protecting group present, i.e., carbobenzyloxy, tert-butoxycarbonyl, and the like.
  • the hydrolysis can be conducted in any suitable acid or base.
  • Step D can be modified by the formulator to meet the properties of the reagents.
  • Example 1 describes a non-limiting example of the disclosed process for the preparation of a prolyl hydroxylase ester pro-drug.
  • the reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components.
  • the reaction mixture was cooled to room temperature and combined with water (500 mL). A solid began to form. The mixture was cooled to 0 °C to 5 °C and stirred for 3 hours. The resulting solid was collected by filtration and washed with water, then hexane. The resulting cake was dried in vacuo at 40 °C to afford 9.4 g (96% yield) of the desired product as an off-white solid.
  • the reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components.
  • the reaction contents was then cooled to 0 °C to 5 °C with stirring and the pH was adjusted to approximately 2 by the slow addition of 50% aqueous NaOH. Stirring was then continued at 0 °C to 5 °C for 3 hours. The resulting solid was collected by filtration and washed with water, then hexane.
  • the filtrate is concentrated to dryness under reduced pressure and the resulting residue was slurried in methanol (10 mL) for two hours. The resulting solid was collected by filtration and washed with cold methanol (20 mL) then hexane and the resulting cake is dried to afford 0.85 g of the desired product as an off-white solid. The filtrate was treated to afford 0.026 g of the desired product as a second crop. The combined crops afford 0.88 g (68% yield) of the desired product.
  • the formulator can readily scale up the above disclosed synthesis. Disclosed herein below is a synthesis wherein the disclosed process is scaled up for commercial use.
  • reaction solution was agitated and purged with nitrogen through the dip-tube for 30 minutes.
  • Degassed water (413 g) was then charged to the reaction mixture while maintaining a temperature of less than 50 °C 25 hours.
  • the reaction was determined to be complete due to the disappearance of 3,5-dichloro-2-cyanopyridine as measured by TLC analysis using ethyl acetate/methanol (4: 1) as the mobile phase and UV 435 nm to visualize the reaction components.
  • the reaction solution was then cooled to 5 °C and charged with heptane (940 g, 1.375 L) and agitated for 30 minutes. Water (5.5 L) was charged and the mixture was further agitated for 1 hour as the temperature was allowed to rise to 15 °C.
  • the solid product was isolated by filtration and washed with water (5.5 L) followed by heptane (18881 g, 2750 ML). The resulting cake was air dried under vacuum for 18 hours and then triturated with a mixture of 2-propanol (6908 g, 8800 mLO and heptane (1 g, 2200mL0 at 50 °C for 4 hours, cooled to ambient temperature and then agitated at ambient temperature for 1 hour. The product was then isolated by filtration and washed with cold 2-propanol (3450 g, 4395 mL) followed by heptane (3010 g, 4400mL).
  • the reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3- chloro-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components.
  • the reaction mixture was cooled to 5 °C and then charged with water (5580 mL).
  • the resulting slurry was agitated for 3 hours at 5 °C.
  • the solid product was isolated by filtration and washed with water (5580 mL) until the filtrate had a pH of 7.
  • the filter cake was air dried under vacuum for 16 hours.
  • Reagents and conditions (a) NaOH, THF; 2 hr.
  • the mixture was stirred for 2 hours at room temperature after which it was determined by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components that the reaction was complete.
  • the reaction solution was adjusted to pH 1 with concentrated HC1 and the solution was heated at 35 °C under vacuum until all of the tetrahydrofuran had been removed. A slurry forms as the solution is concentrated. With efficient stirring the pH is adjusted to ⁇ 2 with the slow addition of 1 M NaOH. The solid which forms was collected by filtration, washed with water, followed by hexane, then dried under vacuum to afford 0.38 g (88% yield) of the desired product as a white solid.
  • the formulator can readily scale up the above disclosed synthesis. Disclosed herein below is a synthesis wherein the disclosed process is scaled up for commercial use.
  • the mixture was stirred for 2 hours at room temperature after which it was determined by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components that the reaction was complete.
  • the reaction solution was acidified to a pH of 2 with slow addition of 2M HC1 (2359 g).
  • the resulting mixture was concentrated under reduced pressure to a volume of about 7.5 L.
  • Ware (2210 g) was added and the solution cooled to ambient temperature and agitated for 18 hours.
  • the solid product was isolated by filtration and washed with water (6 L). the crude product was transferred back into the reactor and triturated with 2215 g o deionized water at 70 °C for 16 hours.
  • Reagents and conditions (a) EDCI, HOBt, DIPEA, DMF; rt.
  • Scheme IV herein below depicts a non-limiting example the hydrolysis of an amide pro-drug to a prolyl hydroxylase inhibitor after removal of a R 10 protecting group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino} acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino} acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

Description

PROCESS FOR PREPARING
[(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS,
ESTERS AND AMIDES PRIORITY
This Application claims priority from U.S. Provisional Application Serial No.
61/493,536, filed June 6, 2011, the entirety of which is included herein by reference.
FIELD
Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]- alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5- heteroaryl substituted [(3- hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3- hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2- carbonyl]amino} acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitors.
Figure 2 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitor ester prodrugs.
Figure 3 depicts an outline of one embodiment for preparing the disclosed prolyl hydroxylase inhibitor amide prodrugs.
DETAILED DISCLOSURE
The materials, compounds, compositions, articles, and methods described herein may be understood more readily by reference to the following detailed description of specific aspects of the disclosed subject matter and the Examples included therein.
Before the present materials, compounds, compositions, articles, devices, and methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific synthetic methods or specific reagents, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
Also, throughout this specification, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which the disclosed matter pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.
General Definitions
In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:
All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (°C) unless otherwise specified.
By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
A weight percent of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
"Admixture" or "blend" is generally used herein means a physical combination of two or more different components.
Throughout the description and claims of this specification the word "comprise" and other forms of the word, such as "comprising" and "comprises," means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.
As used in the description and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "[(3-hydroxypyridine-2-carbonyl)amino]alkanoic acid" includes mixtures of two or more such [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, reference to "the compound" includes mixtures of two or more such compounds, which can include mixtures of optical isomers (racemic mixtures), and the like.
"Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed, then "less than or equal to" the value, "greater than or equal to the value," and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed, then "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that throughout the application data are provided in a number of different formats and that this data represent endpoints and starting points and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 1 1, 12, 13, and 14 are also disclosed.
The following chemical hierarchy is used throughout the specification to describe and enable the scope of the present disclosure and to particularly point out and distinctly claim the units which comprise the compounds of the present disclosure, however, unless otherwise specifically defined, the terms used herein are the same as those of the artisan of ordinary skill. The term "hydrocarbyl" stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional group, including inorganic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts. Within the broad meaning of the term "hydrocarbyl" are the classes "acyclic hydrocarbyl" and "cyclic hydrocarbyl" which terms are used to divide hydrocarbyl units into cyclic and non-cyclic classes.
As it relates to the following definitions, "cyclic hydrocarbyl" units can comprise only carbon atoms in the ring (i.e., carbocyclic and aryl rings) or these units can comprise one or more heteroatoms in the ring (i.e., heterocyclic and heteroaryl rings). For
"carbocyclic" rings the lowest number of carbon atoms in a ring is 3 carbon atoms;
cyclopropyl. For "aryl" rings the lowest number of carbon atoms in a ring are 6 carbon atoms; phenyl. For "heterocyclic" rings the lowest number of carbon atoms in a ring is 1 carbon atom; diazirinyl, a Ci heterocyclic ring. Ethylene oxide comprises 2 carbon atoms and is a C2 heterocyclic ring. For "heteroaryl" rings the lowest number of carbon atoms in a ring is 1 carbon atom; 1,2,3,4-tetrazolyl, a Ci heteroaryl ring. The terms "heterocycle" and "heterocyclic ring" can also include "heteroaryl rings." The following is a non-limiting description of the units encompassed by the terms "acyclic hydrocarbyl" and "cyclic hydrocarbyl" as used herein.
A. Substituted and unsubstituted acyclic hydrocarbyl:
For the purposes of the present disclosure the term "substituted and unsubstituted acyclic hydrocarbyl" encompasses 3 categories of units:
1) linear or branched alkyl, non-limiting examples of which include, methyl (Ci), ethyl (C2), n-propyl (C3), z'so-propyl (C3), n-butyl (C4), sec-butyl (C4), z'so-butyl (C4), tert- butyl (C4), and the like; substituted linear or branched alkyl, non-limiting examples of which includes, hydroxymethyl (Ci), chloromethyl (Ci), trifluoromethyl (Ci), aminomethyl (Ci), 1-chloroethyl (C2), 2 -hydroxy ethyl (C2), 1,2-difluoroethyl (C2), 3-carboxypropyl (C3), and the like.
2) linear or branched alkenyl, non-limiting examples of which include, ethenyl (C2), 3- propenyl (C3), 1-propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2- methylethen-2-yl) (C3), buten-4-yl (C4), and the like; substituted linear or branched alkenyl, non-limiting examples of which include, 2-chloroethenyl (also 2- chlorovinyl) (C2), 4-hydroxybuten-l-yl (C4), 7-hydroxy-7-methyloct-4-en-2-yl (C9), 7-hydroxy-7-methyloct-3,5-dien-2-yl (C9), and the like.
3) linear or branched alkynyl, non-limiting examples of which include, ethynyl (C2), prop-2-ynyl (also propargyl) (C3), propyn-l-yl (C3), and 2-methyl-hex-4-yn-l-yl (C7); substituted linear or branched alkynyl, non-limiting examples of which include, 5-hydroxy-5-methylhex-3-ynyl (C7), 6-hydroxy-6-methylhept-3-yn-2-yl (Cs), 5-hydroxy-5-ethylhept-3-ynyl (C9), and the like.
B. Substituted and unsubstituted cyclic hydrocarbyl:
For the purposes of the present disclosure the term "substituted and unsubstituted cyclic hydrocarbyl" encompasses 5 categories of units: ) The term "carbocyclic" is defined herein as "encompassing rings comprising from 3 to 20 carbon atoms, in one embodiment from 3 to 10 carbon atoms, in another embodiment from 3 to 7 carbon atoms, in a still further embodiment 5 or 6 carbon atoms, wherein the atoms which comprise said rings are limited to carbon atoms, and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms." The following are non-limiting examples of "substituted and unsubstituted carbocyclic rings" which encompass the following categories of units:
i) carbocyclic rings having a single substituted or unsubstituted hydrocarbon ring, non-limiting examples of which include, cyclopropyl (C3), 2-methyl- cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), 2,3-dihydroxycyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclopentadienyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cycloheptyl (C7), cyclooctanyl (C8), 2,5- dimethylcyclopentyl (C5), 3,5-dichlorocyclohexyl (Ce), 4-hydroxycyclohexyl (Ce), and 3,3,5-trimethylcyclohex- l-yl (Ce).
ii) carbocyclic rings having two or more substituted or unsubstituted fused hydrocarbon rings, non-limiting examples of which include, octahydropentalenyl (C8), octahydro- lH-indenyl (C9), 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl (C9), decahydroazulenyl (C10).
iii) carbocyclic rings which are substituted or unsubstituted bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl,
bicyclo[2.2.1]heptanyl, bicyclo[3.1.1 ]heptanyl, l,3-dimethyl[2.2.1 ]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
) The term "aryl" is defined herein as "units encompassing at least one phenyl or naphthyl ring and wherein there are no heteroaryl or heterocyclic rings fused to the phenyl or naphthyl ring and further each ring can be independently substituted with one or more moieties capable of replacing one or more hydrogen atoms." The following are non-limiting examples of "substituted and unsubstituted aryl rings" which encompass the following categories of units:
i) C6 or Cio substituted or unsubstituted aryl rings; phenyl and naphthyl rings whether substituted or unsubstituted, non-limiting examples of which include, phenyl (Ce), naphthylen- l-yl (Cio), naphthylen-2-yl (Cio), 4-fluorophenyl (Ce), 2- hydroxyphenyl (Ce), 3-methylphenyl (Ce), 2-amino-4-fluorophenyl (Ce), 2-(N,N- diethylamino)phenyl (C6), 2-cyanophenyl (C6), 2,6-di-tert-butylphenyl (C6), 3- methoxyphenyl (Ce), 8-hydroxynaphthylen-2-yl (Cio), 4,5-dimethoxynaphthylen-l- yl (Cio), and 6-cyano-naphthylen-l-yl (Cio).
ii) Ce or Cio aryl rings fused with 1 or 2 saturated rings to afford C8-C20 ring systems, non-limiting examples of which include, bicyclo[4.2.0]octa-l,3,5-trienyl (Cs), and indanyl (C9).
The terms "heterocyclic" and/or "heterocycle" are defined herein as "units comprising one or more rings having from 3 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further the ring which contains the heteroatom is also not an aromatic ring." The following are non-limiting examples of "substituted and unsubstituted heterocyclic rings" which encompass the following categories of units:
i) heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl (Ci), aziridinyl (C2), urazolyl (C2), azetidinyl (C3), pyrazolidinyl (C3), imidazolidinyl (C3), oxazolidinyl (C3), isoxazolinyl (C3), thiazolidinyl (C3), isothiazolinyl (C3), oxathiazolidinonyl (C3), oxazolidinonyl (C3), hydantoinyl (C3), tetrahydrofuranyl (C4), pyrrolidinyl (C4), morpholinyl (C4), piperazinyl (C4), piperidinyl (C4), dihydropyranyl (C5), tetrahydropyranyl (C5), piperidin-2-onyl (valerolactam) (C5), 2,3,4,5-tetrahydro-lH- azepinyl (Ce), 2,3 -dihydro-lH- indole (Cs), and 1,2,3,4-tetrahydroquinoline (C9). ii) heterocyclic units having 2 or more rings one of which is a heterocyclic ring, non-limiting examples of which include hexahydro- lH-pyrrolizinyl (C7),
3a,4,5,6,7,7a-hexahydro-lH-benzo[d]imidazolyl (C7), 3a,4,5,6,7,7a-hexahydro-lH- indolyl (Cs), 1,2,3,4-tetrahydroquinolinyl (C9), and decahydro-lH- cycloocta[b]pyrrolyl (Cio).
The term "heteroaryl" is defined herein as "encompassing one or more rings comprising from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), or mixtures of N, O, and S, and wherein further at least one of the rings which comprises a heteroatom is an aromatic ring." Heteroaryl rings can comprise from 1 to 19 carbon atoms, in another embodiment heteroaryl rings can comprise from 1 to 9 carbon atoms. The following are non-limiting examples of "substituted and unsubstituted heterocyclic rings" which encompass the following categories of units:
heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl (CO, [l,2,3]triazolyl (C2), [l,2,4]triazolyl (C2), triazinyl (C3), thiazolyl (C3), IH-imidazolyl (C3), oxazolyl (C3), isoxazolyl (C3), isothiazolyl (C3), furanyl (C4), thiophenyl (C4), pyrimidinyl (C4), 2-phenylpyrimidinyl (C4), pyridinyl (C5), 3-methylpyridinyl (C5), and 4-dimethylaminopyridinyl (C5) ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7H-purinyl (C5), 9H-purinyl (C5), 6- amino-9H-purinyl (C5), 5H-pyrrolo[3,2-i/]pyrimidinyl (Ce), 7H-pyrrolo[2,3- i/]pyrimidinyl (Ce), pyrido[2,3-i/]pyrimidinyl (C7), 2-phenylbenzo[d]thiazolyl (C7), lH-indolyl (C8), 4,5,6,7-tetrahydro-l-H-indolyl (C8), quinoxalinyl (C8), 5- methylquinoxalinyl (C8), quinazolinyl (C8), quinolinyl (C9), 8-hydroxy-quinolinyl (C9), and isoquinolinyl (C9).
Ci-Ce tethered cyclic hydrocarbyl units (whether carbocyclic units, Ce or C10 aryl units, heterocyclic units, or heteroaryl units) which connected to another moiety, unit, or core of the molecule by way of a Ci-Ce alkylene unit. Non-limiting examples of tethered cyclic hydrocarbyl units include benzyl Ci-(C6) having the formula:
Figure imgf000008_0001
wherein Ra is optionally one or more independently chosen substitutions for hydrogen. Further examples include other aryl units, inter alia, (2- hydroxyphenyl)hexyl C6-(Ce); naphthalen-2-ylmethyl Ci-(Cio), 4-fluorobenzyl Ci- (C6), 2-(3-hydroxyphenyl)ethyl C2-(Ce), as well as substituted and unsubstituted C3- C10 alkylenecarbocyclic units, for example, cyclopropylmethyl Ci-(C3),
cyclopentylethyl C2-(Cs), cyclohexylmethyl C\-(C£);. Included within this category are substituted and unsubstituted C1-C10 alkylene-heteroaryl units, for example a 2- picolyl Ci-(C6) unit having the formula:
Figure imgf000008_0002
wherein Ra is the same as defined above. In addition, C1-C12 tethered cyclic hydrocarbyl units include C1-C10 alkyleneheterocyclic units and alkylene-heteroaryl units, non-limiting examples of which include, aziridinylmethyl Ci-(C2) and oxazol- 2-ylmethyl d-(C3).
For the purposes of the present disclosure carbocyclic rings are from C3 to C20; aryl rings are Ce or Cio; heterocyclic rings are from Ci to C9; and heteroaryl rings are from Ci to C9.
For the purposes of the present disclosure, and to provide consistency in defining the present disclosure, fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be characterized and referred to herein as being encompassed by the cyclic family corresponding to the heteroatom containing ring, although the artisan may have alternative characterizations. For example, 1,2,3,4- tetrahydroquinoline having the formula:
Figure imgf000009_0001
is, for the purposes of the present disclosure, defined as a heterocyclic unit. 6,7-Dihydro- 5H-cyclopentapyrimidine having the formula:
Figure imgf000009_0002
is, for the purposes of the present disclosure, is defined as a heteroaryl unit. When a fused ring unit contains heteroatoms in both a non-aromatic ring (heterocyclic ring) and an aryl ring (heteroaryl ring), the aryl ring will predominate and determine the type of category to which the ring is assigned herein for the purposes of describing the invention. For example, l,2,3,4-tetrahydro-[l,8]naphthpyridine having the formula:
Figure imgf000009_0003
is, for the purposes of the present disclosure, is defined as a heteroaryl unit.
The term "substituted" is used throughout the specification. The term "substituted" is applied to the units described herein as "substituted unit or moiety is a hydrocarbyl unit or moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below." The units, when substituting for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety, or unit. For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. Three hydrogen replacement includes cyano, and the like. The term substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain; can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as "substituted" any number of the hydrogen atoms may be replaced. For example, 4-hydroxyphenyl is a "substituted aromatic carbocyclic ring (aryl ring)", ( ,N-dimethyl-5-amino)octanyl is a " substituted Cs linear alkyl unit, 3-guanidinopropyl is a "substituted C3 linear alkyl unit," and 2-carboxypyridinyl is a "substituted heteroaryl unit."
The following are non-limiting examples of units which can substitute for hydrogen atoms on a carbocyclic, aryl, heterocyclic, or heteroaryl unit:
i) substituted or unsubstituted C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; methyl (Ci), ethyl (C2), ethenyl (C2), ethynyl (C2), n-propyl (C3), «o-propyl (C3), cyclopropyl (C3), 3-propenyl (C3), 1- propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), prop-2-ynyl (also propargyl) (C3), propyn-l-yl (C3), n-butyl (C4), sec- butyl (C4), z'so-butyl (C4), tert-butyl (C4), cyclobutyl (C4), buten-4-yl (C4), cyclopentyl (C5), cyclohexyl (Ci);
ii) substituted or unsubstituted Ce or C10 aryl; for example, phenyl, naphthyl (also referred to herein as naphthylen- 1 -yl (C10) or naphthylen-2-yl (C10)); iii) substituted or unsubstituted C7 or Cn alkylenearyl; for example, benzyl, 2- phenylethyl, naphthylen-2-ylmethyl;
iv) substituted or unsubstituted C1-C9 heterocyclic rings; as described herein below;
v) substituted or unsubstituted C1-C9 heteroaryl rings; as described herein
below;
vi) -(CR102aR102b)aOR101; for example, -OH, -CH2OH, -OCH3, -CH2OCH3, -OCH2CH3, -CH2OCH2CH3, -OCH2CH2CH3, and -CH2OCH2CH2CH3; vii) -(CR102aR102b)aC(O)R101; for example, -COCH3, -CH2COCH3,
-COCH2CH3, -CH2COCH2CH3, -COCH2CH2CH3, and
-CH2COCH2CH2CH3;
viii) -(CR102aR102b)aC(O)OR101; for example, -C02CH3, -CH2C02CH3,
-C02CH2CH3, -CH2C02CH2CH3, -C02CH2CH2CH3, and
-CH2C02CH2CH2CH3;
ix) -(CR102aR102b)aC(O)N(R101)2; for example, -CONH2, -CH2CONH2,
-CONHCH3, -CH2CONHCH3, -CON(CH3)2, and -CH2CON(CH3)2;
x) -(CR102aR102b)aN(R101) C(0)R101 ; for example, -NHCOCH3,
-CH2NHCOCH3, -NHCOCH2CH3, and -CH2NHCOCH2CH3; xi) -(CR102aR102b)aN(R101) C(0)2R101; for example, -NHC02CH3,
-CH2NHC02CH3, -NHC02CH2CH3, and -CH2NHC02CH2CH3; xii) -(CR102aR102b)aN(R101)2; for example, -NH2, -CH2NH2, -NHCH3,
-CH2NHCH3, -N(CH3)2, and -CH2N(CH3)2;
xiii) halogen; -F, -CI, -Br, and -I;
xiv) -(CR102aR102b)aCN;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j ' is an integer from 0 to 2, j ' + k' = 2; for example, -CH2F, -CHF2, -CH2CH2F, -CH2CHF2, -CF3, -CC13, or -CBr3; xvii) -(CR102aR102b)aSR101; -SH, -CH2SH, -SCH3, -CH2SCH3, -SC6H5, and
— CH2SC6H5;
xviii) -(CR102aR102b)aSO2R101; for example, -S02H, -CH2S02H, -S02CH3,
-CH2S02CH3, -S02C6H5, and -CH2S02C6H5; and
xix) -(CR102aR102b)aSO3R101; for example, -S03H, -CH2S03H, -S03CH3,
-CH2S03CH3, -S03C6H5, and -CH2S03C6H5;
wherein each R101 is independently hydrogen, substituted or unsubstituted C 1-C6 linear, C3- C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; R102a and 102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4.
The substitutions for hydrogen defined herein above, for example, substituted Ci-Ci2 linear, C3-Ci2 branched, or C3-Ci2 cyclic alkyl, alkenyl, and alkynyl, substituted Ce or C10 aryl, substituted C7 or Cn alkylenearyl, substituted C1-C9 heterocyclic rings, substituted Ci- C9 heteroaryl rings, and R101, can be optionally substituted by one or more of the following substitutions for hydrogen:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; methyl (Ci), ethyl (C2), ethenyl (C2), ethynyl (C2), n-propyl (C3), z'so-propyl (C3), cyclopropyl (C3), 3-propenyl (C3), 1-propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), prop-2-ynyl (also propargyl) (C3), propyn-l-yl (C3), n-butyl (C4), sec-butyl (C4), z'so-butyl (C4), tert-hutyl (C4), cyclobutyl (C4), buten-4-yl (C4), cyclopentyl (C5), cyclohexyl
(C6);
ii) Ce or Cio aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen-l-yl (Cio) or naphthylen-2-yl (Cio));
iii) C7 or Cn alkylenearyl; for example, benzyl, 2-phenylethyl, naphthylen-2- ylmethyl;
iv) C1-C9 heterocyclic rings; as described herein below;
v) C1-C9 heteroaryl rings; as described herein below;
vi) -(CR202aR202b)bOR201 ; for example, -OH, -CH2OH, -OCH3, -CH2OCH3, -OCH2CH3, -CH2OCH2CH3, -OCH2CH2CH3, and -CH2OCH2CH2CH3; vii) -(CR202aR202b)bC(O)R201; for example, -COCH3, -CH2COCH3,
-COCH2CH3, -CH2COCH2CH3, -COCH2CH2CH3, and
Figure imgf000012_0001
viii) -(CR202aR202b)bC(O)OR201; for example, -CO2CH3, -CH2C02CH3,
-CO2CH2CH3, -CH2CO2CH2CH3, -CO2CH2CH2CH3, and
Figure imgf000012_0002
ix) -(CR202aR202b)bC(O)N(R201)2; for example, -CONH2, -CH2CONH2,
-CONHCH3, -CH2CONHCH3, -CON(CH3)2, and -CH2CON(CH3)2;
x) -(CR202aR202b)bN(R201) C(0)R201; for example, -NHCOCH3,
-CH2NHCOCH3, -NHCOCH2CH3, and -CH2NHCOCH2CH3; xi) -(CR202aR202b)bN(R201) C(0)2R201 ; for example, -NHCO2CH3,
-CH2NHCO2CH3, -NHCO2CH2CH3, and -CH2NHCO2CH2CH3; xii) -(CR202aR202b)bN(R201)2; for example, -NH2, -CH2NH2, -NHCH3,
-CH2NHCH3, -N(CH3)2, and -CH2N(CH3)2;
xiii) halogen; -F, -CI, -Br, and -I; xiv)
xv)
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; for example, -CH2F, -CHF2, -CH2CH2F, -CH2CHF2, -CF3, -CC13, or -CBr3;
xvii) -(CR202aR202b)bSR201; -SH, -CH2SH, -SCH3, -CH2SCH3, -SC6H5, and — CH2SC6H5;
xviii) -(CR202aR202b)bSO2R201; for example, -S02H, -CH2S02H, -S02CH3,
-CH2S02CH3, -S02C6H5, and -CH2S02C6H5; and
xix) -(CR202aR202b)bSO3R201; for example, -S03H, -CH2S03H, -S03CH3,
-CH2S03CH3, -S03C6H5, and -CH2S03C6H5;
wherein each R201 is independently hydrogen, C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R201 units can be taken together to form a ring comprising 3-7 atoms; 202a and R202b are each independently hydrogen or Ci- C4 linear or C3-C4 branched alkyl; the index "b" is from 0 to 4.
For the purposes of the present disclosure the terms "compound," "analog," and "composition of matter" stand equally well for each other and are used interchangeably throughout the specification. The disclosed compounds include all enantiomeric forms, diastereomeric forms, salts, and the like.
The compounds disclosed herein include all salt forms, for example, salts of both basic groups, inter alia, amines, as well as salts of acidic groups, inter alia, carboxylic acids. The following are non-limiting examples of anions that can form salts with protonated basic groups: chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, citrate, and the like. The following are non-limiting examples of cations that can form salts of acidic groups: ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, lysine, tromethamine, meglumine and the like.
The disclosed process can be used to prepare compounds having the formula:
Figure imgf000013_0001
wherein R and R are further defined herein. Compounds having the formula:
Figure imgf000014_0001
wherein L is a linking group defined herein, have been found to exhibit prolyl hydroxylase inhibition (antagonism). Compounds of this formula have also been found to stabilize hypoxia inducible factor-2 alpha (HIF-2a). It has also been found that esters and amides having the formula:
Figure imgf000014_0002
can hydrolyze in vivo, in vitro and ex vivo to the corresponding carboxylic acids shown above. As such, these esters and amides are referred to herein as "prodrugs."
R Units
R units have the formula:
Figure imgf000014_0003
wherein X is chosen from:
i) OH;
ϋ) OR3;
iii) -NR4R5; and
iv) -OM1.
R3 is C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl, or benzyl.
R4 and R5 are each independently hydrogen, C1-C12 linear, C3-C12 branched or C3- C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl; benzyl; or R4 and R5 can be taken together with the nitrogen atom to form a 3 to 10 member ring, wherein the ring can optionally contain one or more heteroatoms chosen from oxygen (O), nitrogen (N), or sulfur (S). M1 represents a cation as further described herein below. When a ring is formed from R4 and R5 and the ring contains a ring nitrogen other than the nitrogen atom to which R4 and R5 are bonded, then the nitrogen atom can have the form -NR9- or =N- wherein R9 can be hydrogen or methyl. Non-limiting examples of this embodiment includes compounds having the formula:
Figure imgf000015_0001
In one aspect, X is hydroxyl, -OH.
In a further aspect, X is -OR3. One embodiment of this aspect relates to X units wherein R3 is Ci-Ce linear alkyl, for example, methyl (Ci), ethyl (C2), n-propyl (C3), n-butyl (C4), n-pentyl (C5), and n-hexyl (Ce). Non-limiting examples include the methyl ester, the ethyl ester, the n-propyl ester, and the like.
Another embodiment of this aspect relates to X units wherein R3 is C3-C6 branched alkyl non-limiting examples of which include z'so-propyl (C3), sec-butyl (C4), iso-butyl (C4), tert-butyl (C4), 1 -methylbutyl (C5), 2-methylbutyl (C5), 3-methylbutyl (C5), and 4- methylpentyl (Ce).
A further embodiment of this aspect relates to X units wherein R3 is C3-C6 cyclic alkyl, for example, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), and cyclohexyl (Ce).
In another aspect, X is -NR4R5. One embodiment of this aspect relates to X units wherein R4 and R5 are both hydrogen; -NH2.
A further embodiment of this aspect relates to X units wherein R4 and R5 are independently chosen from hydrogen, C1-C4 linear alkyl, C3-C4 branched alkyl, or C3-C4 cyclic alkyl, for example, methyl (Ci), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl (C4), sec-butyl (C4), z'so-butyl (C4), and tert-butyl (C4). Non-limiting examples of this embodiment include -NH2, -NHCH3, -N(CH3)2, -NHC2H5, -N(C2H5)2, and - N(CH3)(C2H5).
L is a linking unit having the formula -(CR7aR7b)n- wherein R7a and R7b can be independently chosen from hydrogen, Ci-Ce linear, C3-C6 branched or C3-C6 cyclic alkyl. The index n is an integer from 1 to 4.
In one aspect of L units, R7a and R7b are both hydrogen and the index n is an integer from 1 to 4, i.e., -CH2- (methylene), -CH2CH2- (ethylene), -CH2CH2CH2- (propylene), and -CH2CH2CH2CH2- (butylene). One iteration of L units according to this aspect relates to compounds having the formula:
Figure imgf000016_0001
A further aspect of L units relates to L units wherein R7a and R7b are independently chosen from hydrogen, methyl (Ci), ethyl (C2), n-propyl (C3), and z'so-propyl (C3) and the index n is an integer from 1 to 4. One embodiment of this aspect relates to L units wherein R7a is hydrogen and R7b is chosen from methyl (CO, ethyl (C2), n-propyl (C3), and iso- propyl (C3), and the index n is an integer from 1 or 3. Non-limiting examples of this embodiment includes -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2- -CH(CH3)CH2CH2-, -CH2CH(CH3)CH2- and -CH2CH2CH(CH3)-.
A yet further aspect of L units relates to L units wherein R7a and R7b are
independently chosen from methyl (CO, ethyl (C2), n-propyl (C3), and z'so-propyl (C3) and the index n is an integer from 1 to 4. A non-limiting example of this aspect has the formula -C(CH3)2-.
In a still further aspect of L units, L units can be derived from the reaction of an amino acid with a 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine as described herein below in the disclosure of process step D. One embodiment of this aspect of L relates to L units wherein R7b is hydrogen and R7a is chosen from hydrogen, methyl, z'sopropyl, iso- butyl, sec-butyl, hydroxymethyl, 1 -hydroxy ethyl, thiomethyl, 2-(methylthio)ethyl, benzyl, (4-hydroxyphenyl)methyl, indol-3-ylmethyl, imidazol-4-ylmethyl, 3-gunidinylpropyl, 4- aminobutyl, carboxymethyl, 2-carboxyethyl, acetamide, or R8 and R7a can be taken together to form a pyrrolidinyl ring, for example, when proline is reacted with the 5-aryl or 5- heteroaryl-3-hydroxy-2-carboxypyridine.
The index n can be any integer from 1 to 4, for example n can equal 1, n can equal 2, n can equal 3, and n can equal 4.
R8 is hydrogen, methyl (CO or ethyl (C2). In one aspect R8 is hydrogen. In a further aspect R8 is methyl (CO- In another aspect R8 is ethyl (C2).
R1 Units
R1 units are chosen from:
i) substituted or unsubstituted Ce or C10 aryl; and
ii) substituted or unsubstituted C1-C9 heteroaryl. Non-limiting examples of substitutions for a hydrogen atom on R1 units, or alternatively an R10 unit when R1 is represented by an A ring, include:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; for example, methyl (Ci), ethyl (C2), ethenyl (C2), ethynyl (C2), n-propyl (C3), z'so-propyl (C3), cyclopropyl (C3), 3-propenyl (C3), 1-propenyl (also 2- methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), prop-2-ynyl (also propargyl) (C3), propyn-l-yl (C3), n-butyl (C4), sec-butyl (C4), iso- butyl (C4), tert-butyl (C4), cyclobutyl (C4), buten-4-yl (C4), cyclopentyl (C5), cyclohexyl (Ce);
ii) Ce or Cio aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen-l-yl (Cio) or naphthylen-2-yl (Cio));
iii) C7 or C11 alkylenearyl; for example, benzyl, 2-phenylethyl, naphthylen-2- ylmethyl;
iv) C1-C9 heterocyclic rings; as described herein below;
v) C1-C9 heteroaryl rings; as described herein below;
vi) -(CR102aR102b)aOR101; for example, -OH, -CH2OH, -OCH3, -CH2OCH3, -OCH2CH3, -CH2OCH2CH3, -OCH2CH2CH3, and -CH2OCH2CH2CH3; vii) -(CR102aR102b)aC(O)R101; for example, -COCH3, -CH2COCH3,
-COCH2CH3, -CH2COCH2CH3, -COCH2CH2CH3, and
Figure imgf000017_0001
viii) -(CR102aR102b)aC(O)OR101; for example, -C02CH3, -CH2C02CH3,
-CO2CH2CH3, -CH2CO2CH2CH3, -CO2CH2CH2CH3, and
Figure imgf000017_0002
ix) -(CR102aR102b)aC(O)N(R101)2; for example, -CONH2, -CH2CONH2,
-CONHCH3, -CH2CONHCH3, -CON(CH3)2, and -CH2CON(CH3)2;
x) -(CR102aR102b)aN(R101) C(0)R101; for example, -NHCOCH3,
-CH2NHCOCH3, -NHCOCH2CH3, and -CH2NHCOCH2CH3;
xi) -(CR102aR102b)aN(R101) C(0)2R101; for example, -NHC02CH3,
-CH2NHCO2CH3, -NHCO2CH2CH3, and -CH2NHCO2CH2CH3;
xii) -(CR102aR102b)aN(R101)2; for example, -NH2, -CH2NH2, -NHCH3,
-CH2NHCH3, -N(CH3)2, and -CH2N(CH3)2;
xiii) halogen; -F, -CI, -Br, and -I;
xiv) -(CR102aR102b)aCN; xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; for example, - CH2F, -CHF2, -CF3, -CCI3, or -CBr3;
xvii) -(CR102aR102b)aSR101; -SH, -CH2SH, -SCH3, -CH2SCH3, -SC6H5, and — CH2SC6H5;
xviii) -(CR102aR102b)aSO2R101; for example, -S02H, -CH2S02H, -S02CH3,
-CH2S02CH3, -S02C6H5, and -CH2S02C6H5; and
xix) -(CR102aR102b)aSO3R101; for example, -S03H, -CH2S03H, -S03CH3,
-CH2S03CH3, -S03C6H5, and -CH2S03C6H5; or
xx) two substitutions for hydrogen can be taken together to form a substituted or unsubstituted C2-Cs heterocyclic ring, wherein the ring substitution can be one or more of the substitutions defined in (i) to (xix) herein above and the ring can comprise one or more heteroatoms chosen from oxygen (O) sulfur (S), or nitrogen (N);
wherein each R101 is independently hydrogen, substituted or unsubstituted Ci-Ce linear, C3- Ce branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; 102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4.
Stated in another way, the disclosed process relates to the formation of compounds having the formula:
Figure imgf000018_0001
wherein the A ring represents R1 units wherein R1 can be:
i) substituted or unsubstituted Ce or C10 aryl; and
ii) substituted or unsubstituted C1-C9 heteroaryl;
wherein the substitutes for hydrogen atoms on the A ring are one or more R10 units that are independently chosen and further described herein. One aspect of R1 relates to substituted or unsubstituted Ce aryl, i.e., substituted or unsubstituted phenyl. A first embodiment of this aspect relates to R1 equal to phenyl, for example, compounds having the formula:
Figure imgf000019_0001
A further aspect of R1 relates to R1 units that are substituted phenyl having the formula:
Figure imgf000019_0002
wherein R represents from 1 to 5 independently chosen substitutions for hydrogen; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted Ce aryl ring (phenyl), a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
One embodiment of this aspect of R1 units relates to compounds comprising substitutions on R1 of one or more units independently chosen from:
i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl;
ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; and
iii) halogen: -F, -CI, -Br, and -I.
One iteration of this embodiment relates to compounds comprising one or more R10 units that are halogen, thereby forming the following non-limiting examples of R1 units: 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5- difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4- dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3,5-dichlorophenyl,
2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl,
2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4- dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5- trichlorophenyl, 3,4,5-trichlorophenyl, and 2,4,6-trichlorophenyl. A further iteration relates to compounds comprising one or more R units that are C1-C4 linear, C3-C4 branched or C3-C4 cyclic alkyl, thereby forming the following non- limiting examples of R1 units: 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,3- dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4- dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5- trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3- diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6- triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.
Another iteration relates to compounds comprising one or more R10 units that are
C1-C4 linear, C3-C4 branched or C3-C4 cyclic alkoxy, thereby forming the following non- limiting examples of R1 units: 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3- dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4- dimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6- trimethoxyphenyl, 2,4,5 -trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-ethoxyphenyl, 3- ethoxyphenyl, 4-ethoxyphenyl, 2,3-diethoxyphenyl, 2,4-diethoxyphenyl, 2,5- diethoxyphenyl, 2,6-diethoxyphenyl, 3,4-diethoxyphenyl, 2,3,4-triethoxyphenyl, 2,3,5- triethoxyphenyl, 2,3,6-triethoxyphenyl, 2,4,5-triethoxyphenyl, 2,4,6-triethoxyphenyl, 2- isopropoxyphenyl, 3-isopropoxyphenyl, and 4-isopropoxyphenyl.
A yet still further iteration relates to compounds comprising one or more R10 units that comprise at least one of each substitution chosen from C1-C4 linear or halogen, thereby forming the following non-limiting examples of R1 units: 2-chloro-3-methylphenyl, 2- chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-6-methylphenyl, 3-chloro-2- methylphenyl, 3-chloro-4-methylphenyl, 3-chloro-5-methylphenyl, 3-chloro-6-methyl- phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluoro-5-methylphenyl, 2- fluoro-6-methylphenyl, 3-fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl, 3-fluoro-5- methylphenyl, and 3-fluoro-6-methylphenyl.
One embodiment of this aspect of R1 units relates to compounds comprising one or more R10 units independently chosen from:
Figure imgf000020_0001
iii) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2. On iteration of this embodiment relates to compounds comprising one or more R units that are -(CH2)aC , wherein the index a is 0 or 1 , thereby forming the following non- limiting examples of R1 units: 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2- (cyanomethyl)phenyl, 3-(cyanomethyl)phenyl, 4-(cyanomethyl)phenyl, 2,3-dicyanophenyl, 3,4-dicyanophenyl, and 3,5-dicyanophenyl.
Another iteration of this embodiment relates to compounds comprising one or more R10 units that are -(CH2)aN02, wherein the index a is 0 or 1, thereby forming the following non-limiting examples of R1 units: 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2- (nitromethyl)phenyl, 3-(nitromethyl)phenyl, 4-(nitromethyl)phenyl, 2,3-dinitrophenyl, 3,4- dinitrophenyl, and 3,5-dinitrophenyl.
A further iteration of this embodiment relates to compounds comprising one or more R10 units that are -CHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3, wherein the index a is 0 or 1, thereby forming the following non-limiting examples of R1 units: -CH2F, -CH2CH2F, -CHF2, -CH2CHF2, -CF3, -CH2CF3, -CHFCH2F, -CF2CHF2,
CF2CF3, -CH2C1, -CH2CH2C1, -CHC12, -CH2CHC12, -CC13, -CH2CC13, -CHC1CH2C1,
Figure imgf000021_0001
iii) (CRiu aRiu b)aN(Riui)c(0)2R 1i 01
One iteration of this embodiment relates to compounds comprising one or more R units that are -(CR102aR102b)aN(R101)2, wherein the index a is 0 or 1, thereby forming the following non-limiting examples of R1 units: 2-aminophenyl, 3-aminophenyl, 4- aminophenyl, 2,3-diaminophenyl, 3,4-diaminophenyl, 3,5-diaminophenyl, 2- methylaminophenyl, 3-methylaminophenyl, 4-methylaminophenyl, 2,3- (dimethylamino)phenyl, 3,4-(dimethylamino)phenyl, 3,5-(dimethylamino)phenyl, 2,3,4- triaminophenyl, 2,3,5-triaminophenyl, 2,3,6-triaminophenyl, 2,4,5-triaminophenyl, 2,4,6- triaminophenyl, 2,4-(dimethylamino)phenyl, 2,5-(dimethylamino)phenyl, 2,6- (dimethylamino)phenyl, 3,4-(dimethylamino)phenyl, 2,3,4-(dimethylamino)phenyl, 2,3,5- (dimethylamino)phenyl, 2,3,6-(dimethylamino)phenyl, 2,4,5-(dimethylamino)phenyl, 3,4,5- (dimethylamino)phenyl, and 2,4,6-(dimethylamino)phenyl. Another iteration of this embodiment relates to compounds comprising one or more R10 units that are -(CR102aR102b)aC(O)N(R101)2, wherein R101 is chosen from hydrogen, d- Ce linear, C3-C6 branched alkyl or C3-C6 cyclic alkyl, and the index a is 0 or 1 , thereby forming the following non- limiting examples of R1 units: -C(0)NH2, -C(0)NHCH3, -CH2C(0)NHCH3, -C(0)N(CH3)2, -CH2C(0)N(CH3)2, -C(0)NHCH2CH3,
-CH2C(0)NHCH2CH3, -C(0)N(CH2CH3)2, -CH2C(0)N(CH2CH3)2, -C(0)NHCH(CH3)2, -CH2C(0)NHCH(CH3)2, -C(0)N[CH(CH3)2]2, and -CH2C(0)N[CH(CH3)2]2.
Another iteration of this embodiment relates to compounds comprising one or more R10 units that are -(CR102aR102b)aC(O)N(R101)2, wherein two R101 units are taken together to form a ring having from 3 to 7 atoms and the index a is 0 or 1, thereby forming R1 units having, for example, the formulae:
Figure imgf000022_0001
A further iteration of this embodiment relates to compounds comprising one or more
R10 units that are -(CR102aR102b)aN(R101)C(O)2R101; wherein R101 is chosen from hydrogen, C1-C6 linear, C3-C6 branched alkyl or C3-C6 cyclic alkyl, and the index a is 0 or 1 , thereby forming the following non-limiting examples of R1 units: -NHC(0)CH3,
-CH2NHC(0)CH3, -NHC(0)CH2CH3, -CH2NHC(0)CH2CH3, -NHC(0)CH2CH2CH3, -CH2NHC(0)CH2CH2CH3, -NHC(0)(cyclopropyl), and -CH2NHC(0)(cyclopropyl). Another aspect of R1 relates to R1 units that are substituted or unsubstituted Ci- heteroaryl. One embodiment of this aspect relates to R1 equal to C1-C9 heteroaryl, for example, compounds having the formula:
Figure imgf000023_0001
wherein ring A represent a C1-C9 heteroaryl unit non-limiting examples of which include: 1,2,3,4-tetrazolyl (CO, [l,2,3]triazolyl (C2), [l,2,4]triazolyl (C2), [l,2,4]oxadiazolyl (C2), [l,3,4]oxadiazolyl (C2), [l,2,4]thiadiazolyl (C2), [l,3,4]thiadiazolyl (C2), isothiazolyl (C3), thiazolyl (C3), imidazolyl (C3), oxazolyl (C3), isoxazolyl (C3), pyrazolyl (C3), pyrrolyl (C4), furanyl (C4), thiophenyl (C4), triazinyl (C3), pyrimidinyl (C4), pyrazinyl (C4), pyridazinyl (C4), pyridinyl (C5), purinyl (C5), xanthinyl (C5), hypoxanthinyl (C5), benzimidazolyl (C7), indolyl (C8), quinazolinyl (C8), quinolinyl (C9), and isoquinolinyl (C9).
In a further embodiment of this aspect the C1-C9 heteroaryl unit can be bonded to the core pyridine ring at any suitable position, non-limiting examples of which include:
i)
Figure imgf000023_0002
Figure imgf000024_0001
Figure imgf000025_0001
xviii)
Figure imgf000025_0002
xiv)
Figure imgf000025_0003
Another embodiment of this aspect relates to R1 units equal to substituted C1-C9 heteroaryl, for example, compounds having the formula:
Figure imgf000025_0004
wherein ring A represent a C1-C9 heteroaryl unit non-limiting examples of which include: 1,2,3 ,4-tetrazolyl (CO, [l,2,3]triazolyl (C2), [l,2,4]triazolyl (C2), [l,2,4]oxadiazolyl (C2), [l,3,4]oxadiazolyl (C2), [l,2,4]thiadiazolyl (C2), [l,3,4]thiadiazolyl (C2), isothiazolyl (C3), thiazolyl (C3), imidazolyl (C3), oxazolyl (C3), isoxazolyl (C3), pyrazolyl (C3), pyrrolyl (C4), furanyl (C4), thiophenyl (C4), triazinyl (C3), pyrimidinyl (C4), pyrazinyl (C4), pyridazinyl (C4), pyridinyl (C5), purinyl (C5), xanthinyl (C5), hypoxanthinyl (C5), benzimidazolyl (C7), indolyl (C8), quinazolinyl (C8), quinolinyl (C9), and isoquinolinyl (C9).
Non-limiting examples of substitutions for a hydrogen atom on R1 C1-C9 heteroaryl units include:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; methyl (Ci), ethyl (C2), ethenyl (C2), ethynyl (C2), n-propyl (C3), z'so-propyl (C3), cyclopropyl (C3), 3-propenyl (C3), 1-propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), prop-2-ynyl (also propargyl) (C3), propyn-l-yl (C3), n-butyl (C4), sec-butyl (C4), z'so-butyl (C4), tert-butyl (C4), cyclobutyl (C4), buten-4-yl (C4), cyclopentyl (C5), cyclohexyl
(C6);
ii) Ce or Cio aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen-l-yl (C10) or naphthylen-2-yl (C10));
iii) C7 or Cn alkylenearyl; for example, benzyl, 2-phenylethyl, naphthylen-2- ylmethyl;
iv) C1-C9 heterocyclic rings; as described herein below;
v) C1-C9 heteroaryl rings; as described herein below;
vi) -(CR102aR102b)aOR101; for example, -OH, -CH2OH, -OCH3, -CH2OCH3, -OCH2CH3, -CH2OCH2CH3, -OCH2CH2CH3, and -CH2OCH2CH2CH3; vii) -(CR102aR102b)aC(O)R101; for example, -COCH3, -CH2COCH3,
-COCH2CH3, -CH2COCH2CH3, -COCH2CH2CH3, and
-CH2COCH2CH2CH3;
viii) -(CR102aR102b)aC(O)OR101; for example, -C02CH3, -CH2C02CH3,
-C02CH2CH3, -CH2C02CH2CH3, -C02CH2CH2CH3, and
-CH2C02CH2CH2CH3;
ix) -(CR102aR102b)aC(O)N(R101)2; for example, -CONH2, -CH2CONH2,
-CONHCH3, -CH2CONHCH3, -CON(CH3)2, and -CH2CON(CH3)2; x) -(CR102aR102b)aN(R101) C(0)R101; for example, -NHCOCH3,
-CH2NHCOCH3, -NHCOCH2CH3, and -CH2NHCOCH2CH3; xi) -(CR102aR102b)aN(R101) C(0)2R101; for example, -NHC02CH3,
-CH2NHC02CH3, -NHC02CH2CH3, and -CH2NHC02CH2CH3;
xii) -(CR102aR102b)aN(R101)2; for example, -NH2, -CH2NH2, -NHCH3,
-CH2NHCH3, -N(CH3)2, and -CH2N(CH3)2;
xiii) halogen; -F, -CI, -Br, and -I;
xiv) -(CR102aR102b)aCN;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to
2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; for example, - CH2F, -CHF2, -CF3, -CC13, or -CBr3;
xvii) -(CR102aR102b)aSR101; -SH, -CH2SH, -SCH3, -CH2SCH3, -SC6H5, and — CH2SC6H5;
xviii) -(CR102aR102b)aSO2R101; for example, -S02H, -CH2S02H, -S02CH3,
-CH2S02CH3, -S02C6H5, and -CH2S02C6H5; and
xix) -(CR102aR102b)aSO3R101; for example, -S03H, -CH2S03H, -S03CH3,
-CH2S03CH3, -S03C6H5, and -CH2S03C6H5;
wherein each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3- Ce branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; 102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4.
Non-limiting examples of substituted C5-C9 R1 heteroaryl units include 2- methylthiazol-4-yl, 2-ethylthiazol-4-yl, 2-(n-propyl)thiazol-4-yl, 2-(¾o-propyl)thiazol-4-yl, 4,5-dimethylthiazol-2-yl, 4-ethyl-5-methylthiazol-2-yl, 4-methyl-5-ethylthiazol-2-yl, 4,5- diethylthiazol-2-yl, 3-methyl-l ,2,4-oxadiazol-5-yl, 4,5-dimethylimidazol-2-yl, 4-ethyl-5- methylimidazol-2-yl, 4-methyl-5-ethylimidazol-2-yl, 4,5-diethylimidazol-2-yl, 2,5- dimethylthiazol-4-yl, 2,4-dimethylthiazol-5-yl, 3 -methyl- l,2,4-oxadiazol-5-yl, 4,5- dimethyloxazol-2-yl, 4-ethyl-5-methyloxazol-2-yl, 4-methyl-5-ethyloxazol-2-yl, 4,5- diethyloxazol-2-yl, 2-methyloxazol-4-yl, 2-ethyloxazol-4-yl, 2-(n-propyl)oxazol-4-yl, 2- (zso-propyl)oxazol-4-yl, 2-methyloxazol-4-yl, 2-ethyloxazol-4-yl, 2-(n-propyl)oxazol-4-yl, 2-(«o-propyl)oxazol-4-yl, 5-methyl[ l,2,4]oxadiazol-3-yl, 5-ethyl[l ,2,4]-oxadiazol-3-yl, 5- propyl[l,2,4]oxadiazol-3-yl, 5-cyclopropyl[l,2,4]oxadiazol-3-yl, 3-methyl[l,2,4]oxadiazol- 5-yl, 3-ethyl[l,2,4]oxadiazol-5-yl, 3-(n-propyl)[l,2,4]oxadiazol-5-yl, 3-(iso- propyl)[l,2,4]oxadiazol-5-yl, 2,5-dimethylthiazol-4-yl, 2,4-dimethylthiazol-5-yl, 4- ethylthiazol-2-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 4,5-dimethylpyrimidin-2-yl, 4,5- diethylpyrimidin-2-yl, 4-methyl-5-ethyl-pyrimidin-2-yl, 4-ethyl-5-methyl-pyrimidin-2-yl, 4- (thiophen-2-yl)pyrimidin-2-yl, 5-(thiophen-2-yl)pyrimidin-2-yl, 4-(thiophen-3- yl)pyrimidin-2-yl, and 5-(thiophen-2-yl)pyrimidin-3-yl.
Non-limiting examples of substituted C2-C4 5-member heteroaryl rings include:
Figure imgf000028_0001
vii)
Figure imgf000029_0001
A yet further aspect of R1 units relates to rings comprising two R10 substitutions for hydrogen that are taken together to form a substituted or unsubstituted C2-C8 heterocyclic ring. One embodiment of this aspect relates to R1 units wherein two R10 units are taken together to form a substituted or unsubstituted C7-C9 heterocyclic R1 ring system wherein the heterocyclic ring formed by the two R10 substitutions contains one or more nitrogen atoms. No -limiting iterations of this embodiment include R1 units having the formulae:
Figure imgf000029_0002
Another embodiment of this aspect relates to R1 units wherein two R10 units are taken together to form a substituted or unsubstituted C7-C9 heterocyclic R1 ring system wherein the heterocyclic ring formed by the two R10 substitutions contains one or more oxygen atoms. Non-limiting iterations of this embodiment include R1 units having the formulae:
Figure imgf000029_0003
R2 Units
R2 units are chosen from C1-C12 linear alkyl or C3-C12 branched alkyl. In one embodiment R2 can represent hydrogen. In another embodiment, R2 is C1-C4 linear alkyl. Non-limiting examples include methyl, ethyl and n-propyl. In one example, R2 is methyl. R2 units relate to the alkoxide unit having the formula:
0 OR2 that is used in the process disclosed herein. As it relates to the alkoxide, the alkoxide can be derived from any suitable source, i.e., sodium methoxide, lithium ethoxide, and the like which the formulator can choose.
A further aspect of the present disclosure relates to a process for preparing intermediates having the formula:
Figure imgf000030_0001
wherein Rxis the same as defined herein above. This aspect also includes salts of acids, for example, compounds having the formula:
Figure imgf000030_0002
wherein M is a salt forming cation and N represents the cationic charge on M and the number of corresponding anionic units of the disclosed intermediates. The M units can comprise in one embodiment inorganic cations, inter alia, ammonium, sodium, lithium, potassium, calcium, magnesium, bismuth, and the like. In another embodiment, M units can comprise organic cation forming units, inter alia, lysine, ornithine, glycine, alanine, or other amino acids, basic organic compounds, inter alia, methylamine, dimethylamine, trimethylamine, and the like.
Another aspect of the present disclosure relates to a process for preparing intermediates having the formula:
Figure imgf000030_0003
wherein W is a salt forming anion and Y represents the anionic charge on W and the number of corresponding number of the disclosed intermediates in this salt form. The W units can comprise in one embodiment inorganic anions, inter alia, chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, and the like. In another embodiment, W units can comprise organic anion forming units, inter alia, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, citrate, and the like.
In one aspect, the disclosed prolyl hydroxylase inhibitors can be isolated as a pharmaceutically acceptable salt having the formula:
Figure imgf000031_0001
wherein M is a salt forming cation and N represents the cationic charge on M and the number of corresponding anionic units present in the salt.
One aspect of the disclosed salts relates to prolyl hydroxylase inhibitors in the of the mono-valent salt having the formula:
Figure imgf000031_0002
wherein M represents an inorganic or organic cation. Non-limiting examples of monovalent cations include sodium, lithium, potassium, ammonium, silver, organic cations having the formula HN+RaRbRc wherein Ra, Rb and Rc are each independently:
i) hydrogen;
ii) substituted or unsubstituted C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl;
iii) substituted or unsubstituted benzyl;
wherein one or more of Ra, Rb and Rc can be independently substituted by one or more units chosen from:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkoxy;
ii) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic haloalkoxy;
iii) halogen;
iv) hydroxyl;
v) thio; or
vi) one or more of Ra, Rb and Rc can contain one or more units capable of
forming a cation, anion, or zwitterions. One iteration of this embodiment relates to cations wherein each of Ra, Rb and Rc are hydrogen or C1-C12 linear alkyl. Non-limiting examples include methyl ammonium
[HN+H2(CH3)], dimethyl ammonium [HN+H(CH3)2], trimethyl ammonium [HN+(CH3)3], ethyl ammonium [HN+H2(CH2CH3)], diethyl ammonium [HN+H(CH2CH3)2], triethyl ammonium [HN+(CH2CH3)3], dimethylethyl ammonium [HN+(CH3)2(CH2CH3)], and methyldiethyl ammonium [HN+(CH3)(CH2CH3)2].
Another iteration of this embodiment relates to cations wherein one or more of Ra, Rb and Rc are chosen from hydrogen, unsubstituted Ci-Ci2 linear, C3-Ci2 branched, or C3- Ci2 cyclic alkyl or substituted Ci-Ci2 linear, C3-Ci2 branched, or C3-Ci2 cyclic alkyl. One embodiment relates to organic cations having one or more Ci-Ci2 linear, C3-Ci2 branched, or C3-Ci2 cyclic alkyl chains substituted with hydroxy. Non-limiting examples include 2- hydroxyethyl ammonium (cation of monoethanolamine, cholinate) [HN+H2(CH2CH2OH)], methyl-2-hydroxyethyl ammonium [H2N+(CH3)(CH2CH2OH)], di(2 -hydroxyethyl) ammonium [H2N+(CH2CH2OH)2], tri(2-hydroxyethyl) ammonium [HN+(CH2CH2OH)3], and tris(hydroxymethyl)methyl ammonium (cation of tris(hydroxymethyl)aminomethane) [H3N+C[(CH2OH)]3]. Also included are cations formed from amino sugars, for example, amino sugars having the formula H2N (CH3)[(CHOH)nCH2OH] wherein n is from 1 to 7. A non-limiting example of an amino sugar suitable for forming an organic cation is meglumine ( 1 -deoxy- 1 -methylamino-sorbitol).
A further iteration of this embodiment relates to cations formed from amino acids. Non-limiting examples include lysine, ornithine, arginine, glutamine, and the like.
Another aspect of organic amines suitable for forming salts of the disclosed stabilizer include amines wherein one or more of Ra, Rb and Rc are taken together to form a heterocyclic ring that can comprise from 3 to 20 atoms and optionally one or more heteroatoms chosen from nitrogen, oxygen and sulfur. Non-limiting examples include piperazine, piperidine, morpholine, thiomorpholine, and the like.
In addition, di-valent cations can be used wherein the salts of these examples have the formula:
Figure imgf000032_0001
Non-limiting examples of di-valent cations includes calcium magnesium, barium and the like.
Another exam le of salts includes the di-anions havin the formula:
Figure imgf000033_0001
wherein M is the same as defined herein above.
The importance of the herein disclosed intermediates lies in the fact that the formulator can prepare an admixture comprising a plurality of final compounds in one step by the choice of reactants in the final process step as described herein. For example, it is known by the artisan that, although two or more analogs can have approximately equal pharmacological activity, other properties such as bioavailability can be different. Using the disclosed intermediates to form admixtures of final analogs can provide the formulator with a final composition which utilizes the disparate pharmacological activities of the molecules to provide for a constant level of a desired property. For example, one analog in the admixture can have immediate bioavailability while a second or third compound has a slower bioavailability which can provide a pharmacologically active composition that has a steady or near steady level of drug active in a user.
PROCESS
Disclosed herein is a process for preparing the herein above disclosed [(5-phenyl-3- hydroxypyridine-2-carbonyl)-amino]alkanoic acids and [(5-heteroaryl-3-hydroxypyridine- 2-carbonyl)-amino]alkanoic acids. As disclosed herein, the 5-phenyl and 5-heteroaryl rings can be substituted by one or more independently chosen substitutions for hydrogen.
The following is a summary of the steps that comprise the disclosed process.
Step A
Figure imgf000033_0002
Al A2 A3 Step A relates to the condensation of an aryl or heteroaryl borate precursor, Al, and a 3,5-dihalo-2-cyanopyridine, A2, wherein each Z is independently chloro or bromo, to form a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine, A3.
The borate precursor, Al, comprises ring A wherein ring A can be:
A) substituted or unsubstituted Ce or Cio aryl; and
ii) substituted or unsubstituted C1-C9 heteroaryl;
wherein the substitutes for hydrogen atoms on the A ring are one or more R10 units that are independently chosen and further described herein. Y is OR20, wherein R20 is hydrogen or C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, or two OR20 units can be taken together to form a 5-member to 7-member C3-C10 cyclic ester, for example, a cyclic ester having the formula:
Figure imgf000034_0001
One aspect of borate precursor to phenyl boronic acid having the formula:
Figure imgf000034_0002
Another aspect of borate precursors relates to substituted boronic acids having the formula:
Figure imgf000034_0003
wherein R represents from 1 to 5 substitutions as defined herein above. Non-limiting examples of this aspect includes borate precursors having the formula:
Figure imgf000034_0004
The 3,5-dihalo-2-cyanopyridine, A2, is chosen from 3,5-dichloro-2-cyanopyridine, 3-chloro-5-bromo-2-cyanopyridine, 3,5-dibromo-2-cyanopyridine and 3-bromo-5-chloro-2- cyanopyridine. Step A is conducted in the presence of a catalyst, for example, a Suzuki coupling catalyst. The formulator can choose the catalyst and conditions that are compatible with the reagents, i.e., borate precursor and 3,5-dihalo-2-cyanopyridine. (See, Suzuki, A. Pure Appl. Chem.1991, 63, 419-422; Suzuki, A., J. OrganometalUc Chem. 1999, 576, 147-168;
Barder, T. E. et ah, "Catalysts for Suzuki-Miyaura Coupling Processes: Scope and Studies of the Effect of Ligand Structure," J. Am. Chem. Soc. 2005, 127, 4685-4696 included herein by reference in their entirety.)
In one embodiment, the catalyst is [l,l '-bis(diphenyphosphino)ferrocene]dichloro- palladium(II) [PdCl2(dppf)].
Another category of catalysts include ortho-metalated catalysts with alkylphosphine ligands of the general formula [Pd(X)(K2N,C-C6H4CH2NMe2)(PR3)] wherein R is Cy, X is trifluoroacetate, trifluoromethanesufonyl, chloro, or iodo; PR3 is PCy2(o-biphenyl), X is trifluoroacetate). Non-limiting examples of this category include [{Pd^-TFA)(K2N,C-
Figure imgf000035_0001
The catalyst can be preformed, for example, purchased from a chemical supplier or the catalyst can be generated in situ. One non-limiting example of Step A wherein the catalyst is generated in situ includes the following procedure. Pd(OAc)2 (1.5 mmol %), 3,3 '-dimethyl- l, (2,4-bismethylenemesitylene)(4,4,5,6-tetrahydropyrimidinium) chloride (1.5 mmol %), a borate precursor (1.5 mmol), a 3,5-dihalo-2-cyanopyridine (1.0 mmol), K2C03 (2 mmol), water (3 mL)-DMF (3 mL) are added to a small Schlenk tube and the mixture heated at 80 °C for 5 hours. At the conclusion of the reaction, the mixture is collected, removed by extraction with suitable solvent, and the desired product isolated by methods known to the artisan.
Step A is conducted in the presence of a base. Non-limiting examples of suitable bases that can be used in Step A includes LiOH, NaOH, KOH, Ca(OH)2, Li2C03, Na2C03, K2C03; and CaC03. In one embodiment, the base is K2C03. In another embodiment, the base is Na2C03.
Step A can be optionally conducted in the presence of a solvent. Non-limiting examples of solvents include water, formic acid, acetic acid; alcohols, for example, methanol, ethanol, 2,2,2-trichlorethanol, propanol, isopropanol, butanol, tert-butanol, and the like; ketones, for example, acetone, methyl ethyl ketone, diethyl ketone, and the like; esters, for example, methyl acetate, ethyl acetate, methyl propionate, ethyl propionate, and the like; ethers, for example, diethyl ether, methyl tert-butyl ether, tetrahydrofuran, dimethoxyethane, bis(2-methoxyethyl) ether (diglyme), l,4-dioxane,and the like; alkanes, for example, pentane, isopentane, petroleum ether, hexane, mixtures of hexanes, cyclohexane, 35eptanes, isoheptane, octane, isooctane, and the like; halogenated solvents, for example, dichloromethane, chloroform, carbon tetrachloride, 1, 1-dichloroethane, 1, 1, 1- trichloroethane, 1,2-dichloroethane, chlorobenzene, and the like; aromatic hydrocarbons, for example, benzene, toluene, 1,2-dimethylbenzene (ort/zoxylene), 1,3-dimethylbenzene (meto-xylene), 1 ,4-dimetylbenzene (para-xylene), nitrobenzene, and the like; dipolar aprotic solvents, for example, acetonitrile, dimethylsulfoxide, N,N-dimethylformamide, N,N-diethylformamide, N,N-dimethylacetamide, N,N-diethylacetamide, N-methyl-2- pyrrolidinone, carbon disulfide, and hexamethylphosphoramide; and mixtures of one or more solvents.
The reaction can be conducted at any temperature sufficient to provide the desired products or desired products.
Ste B
Figure imgf000036_0001
Step B relates to the conversion of a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine, A3, to a 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine, B.
Compound A3 is reacted with an alkoxide having the formula:
0 OR2
wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl. In one embodiment of step B, intermediate A3 can be reacted with methoxide anion. The methoxide anion can be generated in situ, for example, by the addition of an alkali metal to methanol. In one example, from 1 equivalent to 10 equivalents of sodium metal based upon the amount of A3 to be converted in Step B, is added to an excess of methanol. In another example, an alkali metal is added to an excess of methanol, the solvent removed, and the resulting sodium methoxide retained for use when, for example, Step B is conducted in a solvent other than methanol. In another embodiment, the intermediate A3 can be reacted with ethoxide anion generated from ethanol. In still another embodiment, the intermediate A3 can be reacted with isopropoxy anion generated from isopropanol.
As such, step B can be conducted at any temperature sufficient to provide the desired products or desired products. In addition, step B can be conducted in any solvent or mixtures of solvents that do not react with methoxide anion under the conditions chosen by the formulator.
Ste C
Figure imgf000037_0001
B C
Step C relates to the conversion of the 5-aryl or 5-heteroaryl-3-alkoxy-2- cyanopyridine formed in step B to form a 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine, C, (5-aryl or 5-heteroaryl-3-hydroxypicolinic acid). This conversion can be conducted in the presence of any acid capable of hydrolysis of the cyano moiety to a carboxylic acid moiety and the methoxy moiety to a hydroxyl moiety. In one embodiment, 48% aqueous HBr can be used. In another embodiment, 37% aqueous HC1 can be used.
The compounds having formula C can be isolated as the free acid or as a salt, for example, as a compound having the formula:
Figure imgf000037_0002
as further described herein. Depending upon the intended use of the products of step C, the formulator can proceed to step D or retain the products of step C for use in preparing admixtures of prolyl hydroxylase inhibitors or for preparing prodrugs of prolyl hydroxylase inhibitors.
Ste D
Figure imgf000038_0001
D l D2
Step D relates to the reaction of the 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine formed in step C with a compound having formula D 1 , wherein X is chosen from -OH, -OR3, -NR4R5 or -OM1 as defined herein above, to form one of the following:
i) a prolyl hydroxylase inhibitor;
ii) a prolyl hydroxylase inhibitor prodrug;
iii) an admixture of prolyl hydroxylase inhibitors;
iv) an admixture of prolyl hydroxylase inhibitor prodrugs; or
v) suitable pharmaceutical salts thereof.
One aspect of step D relates to formation of a prolyl hydroxylase inhibitor according to the following scheme:
Figure imgf000038_0002
D
wherein R7a, R7b, R8 and the index n are defined herein above.
Another aspect of step D relate to formation of a prolyl hydroxylase ester prodrug according to the following scheme:
Figure imgf000039_0001
wherein R3, R7a, R7b, R8 and the index n are defined herein above.
A further aspect of step D relate to formation of a prolyl hydroxylase amide prodrug according to the following scheme:
Figure imgf000039_0002
wherein R4, R5, R7a, R7b, R8 and the index n are defined herein above.
Step D relates to the coupling of a 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxy- pyridine, C, prepared in Step C with an amino acid, amino acid ester, or amino acid amide. Any coupling reagent compatible with the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxy- pyridine, amino acid, amino acid ester, or amino acid amide can be used to prepare the desired prolyl hydroxylase inhibitors or prodrugs thereof. Non-limiting examples of coupling reagents includes carbonyldiimidazole (CDI), dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), and ethyl-(N',N'-dimethylamino)propylcarbodiimide (EDC), (benzotriazol- 1 -yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol- l -yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 0-(benzotriazol-l -yl)-N,N,N'N'-tertaetyluronium hexafluorophosphate (HBTU), O- (benzotriazol- l-yl)-N,N,N'N'-tertamethyluronium tetrafluoroborate (TBTU), 0-(7- azabenzotriazol- l -yl)-N,N,N'N'-tetramethyluronium hexafluorophosphate (HATU), 0-(6- chlorobenzotriazol- l-yl)-N,N,N'N'-tetramethyluronium hexafluorophosphate (HCTU), O- (3,4-dihydro-4-oxo-l ,2,3-benzotriazine-3-yl)-N,N,N'N'-tetramethyluronium
hexafluorophosphate (TDBTU), and 3-(diethylphosphoryloxy)- l ,2,3-benzotriazin-4(3H)- one (DEPBT). In one iteration, wherein R8 is not hydrogen, step D can be conducted with a suitable reagent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP).
A further iteration of the reaction outlined in step D utilizes an in situ generated mixed anhydride of the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine, for example, reacting compound C with a mixed anhydride forming reagent. Non-limiting examples include isobutylchloro-formate (IBCF), ethylchoroformate, isopropylchloroformate, and the like. Other coupling reagents include 2-chloro-3,6-dimethoxy-l,3,5-triazine, pivalolyl chloride and triphosgene. In another iteration, acyl chlorides can be used to activate the carbonyl moiety of compound C for the coupling exemplified in step D.
In a yet further embodiment pivaloyl chloride in THF are used to catalyze the coupling reaction.
An organic or inorganic base can be used for conducting step D. Non-limiting examples of suitable organic bases include diisopropylethylamine, and the like.
Step D can be conducted in one or more solvents. Non-limiting examples of solvents include dimethylformamide (DMF), diethylformamide (DEF), dimethylacetamide (DMA), diethylacetamide(DEA), dimethyl sulfoxide(DMSO), dioxane, and water. In one embodiment, a mixture of water and one or more polar organic solvents can be used, for example, DMF/water, DMSO/water, dioxane/water, DMF/dioxane/water, and the like.
In some embodiments of the disclosed process, due to the type of substitution R10 on ring A, the formulator can form a prodrug prior then further process the prodrug to the final prolyl hydroxylase inhibitor. For example, the intermediate C may comprise an R10 unit that has a protecting group present, i.e., carbobenzyloxy, tert-butoxycarbonyl, and the like. In such examples it can be more convenient for the formulator to form the final product in prodrug form, remove the protecting group then in a Step E, hydrolyze the prodrug to the free acid. The hydrolysis can be conducted in any suitable acid or base.
The conditions of Step D can be modified by the formulator to meet the properties of the reagents.
Scheme I herein below outlines and Example 1 describes a non-limiting example of the disclosed process for the preparation of a prolyl hydroxylase ester pro-drug.
Figure imgf000041_0001
40 EXAMPLE 1
Methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino} acetate (4) Preparation of 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine (1): To a 100 mL round bottom flask adapted for magnetic stirring and equipped with a nitrogen inlet was charged (3-chlorophenyl)boronic acid (5 g, 32 mmol), 3,5-dichloro-2-cyanopyridine (5.8 g, 34 mmol), K2CO3 (5.5 g, 40 mmol), [l, l '-bis(diphenyphosphino)ferrocene]dichloro- palladium(II) [PdCi2(dppf)] (0.1 g, 0.13 mmol), dimethylformamide (50 mL) and water (5mL). The reaction solution was agitated and heated to 45 °C and held at that temperature for 18 hours after which the reaction was determined to be complete due to the
disappearance of 3,5-dichloro-2-cyanopyridine as measured by TLC analysis using ethyl acetate/methanol (4: 1) as the mobile phase and UV 435 nm to visualize the reaction components. The reaction solution was then cooled to room temperature and the contents partitioned between ethyl acetate (250 mL) and saturated aqueous NaCl (100 mL). The organic phase was isolated and washed a second time with saturated aqueous NaCl (100 mL). The organic phase was dried for 4 hours over MgS04, the MgS04 removed by filtration and the solvent removed under reduced pressure. The residue that remained was then slurried in methanol (50 mL) at room temperature for 20 hours. The resulting solid was collected by filtration and washed with cold methanol (50 mL) then hexanes (60 mL) and dried to afford 5.8 g (73% yield) of an admixture containing a 96:4 ratio of the desired regioisomer. XH NMR (DMSO-ifc) δ 9.12 (d, 1H), 8.70 (d, 1H), 8.03 (t, 1H) 7.88 (m, 1H), and 7.58 (m, 2H).
Preparation of 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine (2): To a 500 mL round bottom flask adapted for magnetic stirring and fitted with a reflux condenser and nitrogen inlet was charged with 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine, 1, (10 g, 40 mmol), sodium methoxide (13.8 mL, 60 mmol) and methanol (200 mL). With stirring, the reaction solution was heated to reflux for 20 hours. The reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components. The reaction mixture was cooled to room temperature and combined with water (500 mL). A solid began to form. The mixture was cooled to 0 °C to 5 °C and stirred for 3 hours. The resulting solid was collected by filtration and washed with water, then hexane. The resulting cake was dried in vacuo at 40 °C to afford 9.4 g (96% yield) of the desired product as an off-white solid. ¾ NMR (DMSO-rfe) δ 8.68 (d, 1H), 8.05 (d, 1H), 8.01 (s, 1H) 7.86 (m, 1H), 7.59 (s, 1H), 7.57 (s, 1H) and 4.09 (s, 3H).
Preparation of 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid (3): To a 50 mL round bottom flask adapted for magnetic stirring and fitted with a reflux condenser was charged 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine, 2, (1 g, 4 mmol) and a 48% aqueous solution of HBr (10 mL). While being stirred, the reaction solution was heated to reflux for 20 hours. The reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components. The reaction contents was then cooled to 0 °C to 5 °C with stirring and the pH was adjusted to approximately 2 by the slow addition of 50% aqueous NaOH. Stirring was then continued at 0 °C to 5 °C for 3 hours. The resulting solid was collected by filtration and washed with water, then hexane. The resulting cake was dried in vacuo at 40 °C to afford 1.03 g (quantitative yield) of the desired product as an off-white solid. 'H NMR (DMSO-ifc) δ 8.52 (d, 1H), 7.99 (d, 1H), 7.95 (s, 1H) 7.81 (t, 1H), 7.57 (s, 1H), and 7.55 (s, 1H).
Preparation of methyl { [5 -(3 -chlorophenyl)-3 -hydroxypyridin-2-yl] amino } acetate (4): To a 50 mL round bottom flask adapted for magnetic stirring and fitted with a nitrogen inlet tube was charged 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid, 3, (1 gm, 4 mmol), N,N-carbonyldiimidazole (CDI) (0.97 g, 6 mmol) and dimethyl sulfoxide (5 mL). The reaction mixture was stirred at 45 °C for about 1 hour then cooled to room temperature. Glycine methyl ester hydrochloride (1.15 g, 12 mmol) is added followed by the dropwise addition of diisopropylethylamine (3.2 mL, 19 mmol). The mixture was then stirred for 2.5 hours at room temperature after which water (70 mL) was added. The contents of the reaction flask was cooled to 0 °C to 5 °C and IN HC1 was added until the solution pH is approximately 2. The solution was extracted with dichloromethane (100 mL) and the organic layer was dried over MgS04 for 16 hours. Silica gel (3 g) is added and the solution slurried for 2 hours after which the solids are removed by filtration. The filtrate is concentrated to dryness under reduced pressure and the resulting residue was slurried in methanol (10 mL) for two hours. The resulting solid was collected by filtration and washed with cold methanol (20 mL) then hexane and the resulting cake is dried to afford 0.85 g of the desired product as an off-white solid. The filtrate was treated to afford 0.026 g of the desired product as a second crop. The combined crops afford 0.88 g (68% yield) of the desired product. XH NMR (DMSO-i¾) δ 12.3 (s, 1H), 9.52 (t, 1H), 8.56 (d, 1H), 7.93 (s, 1H), 7.80 (q, 2H), 7.55 (t, 2H), 4.12 (d, 2H), and 3.69 (s, 3H).
The formulator can readily scale up the above disclosed synthesis. Disclosed herein below is a synthesis wherein the disclosed process is scaled up for commercial use.
EXAMPLE 2
Methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino} acetate (4) Preparation of 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine (1): A 20 L reactor equipped with a mechanical stirrer, dip tube, thermometer and nitrogen inlet was charged with (3-chlorophenyl)boronic acid (550 g, 3.52 mol), 3,5-dichloro-2-cyanopyridine (639 g, 3.69 mol), K2CO3 (5.5 g, 40 mmol), [l, l '-bis(diphenyphosphino)ferrocene]dichloro- palladium(II) [PdCl2(dppf)] (11.5 g, 140 mmol), and dimethylformamide (3894 g, 4.125 L). The reaction solution was agitated and purged with nitrogen through the dip-tube for 30 minutes. Degassed water (413 g) was then charged to the reaction mixture while maintaining a temperature of less than 50 °C 25 hours. The reaction was determined to be complete due to the disappearance of 3,5-dichloro-2-cyanopyridine as measured by TLC analysis using ethyl acetate/methanol (4: 1) as the mobile phase and UV 435 nm to visualize the reaction components. The reaction solution was then cooled to 5 °C and charged with heptane (940 g, 1.375 L) and agitated for 30 minutes. Water (5.5 L) was charged and the mixture was further agitated for 1 hour as the temperature was allowed to rise to 15 °C. The solid product was isolated by filtration and washed with water (5.5 L) followed by heptane (18881 g, 2750 ML). The resulting cake was air dried under vacuum for 18 hours and then triturated with a mixture of 2-propanol (6908 g, 8800 mLO and heptane (1 g, 2200mL0 at 50 °C for 4 hours, cooled to ambient temperature and then agitated at ambient temperature for 1 hour. The product was then isolated by filtration and washed with cold 2-propanol (3450 g, 4395 mL) followed by heptane (3010 g, 4400mL). The resulting solid was dried under high vacuum at 40 °C for 64 hours to afford 565.9 g (65% yield) of the desired product as a beige solid. Purity by HPLC was 98.3. ¾ NMR (DMSO-i¾) δ 9.12 (d, 1H), 8.70 (d, 1H), 8.03 (t, 1H) 7.88 (m, 1H), and 7.58 (m, 2H).
Preparation of 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine (2): A 20 L reactor equipped with a mechanical stirred, condenser, thermometer and nitrogen inlet was charged with 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine, 1, (558 g, 2.24 mol) and sodium methoxide (25% solution in methanol, 726.0 g, 3.36 mol). With agitation, the reaction solution was heated to reflux for 24 hours, resulting in a beige-colored suspension. The reaction was determined to be complete due to the disappearance of 5-(3-chlorophenyl)-3- chloro-2-cyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components. The reaction mixture was cooled to 5 °C and then charged with water (5580 mL). The resulting slurry was agitated for 3 hours at 5 °C. The solid product was isolated by filtration and washed with water (5580 mL) until the filtrate had a pH of 7. The filter cake was air dried under vacuum for 16 hours. The filter cake was then charged back to the reactor and triturated in MeOH (2210 g, 2794 mL) for 1 hour at ambient temperature. The solid was collected by filtration and washed with MeOH (882 g, 1 116 mL, 5 °C) followed by heptane (205 mL, 300mL), and dried under high vacuum at 45 °C for 72 hours to afford 448 g (82% yield) of the desired product as an off-white solid. Purity by HPLC was 97.9%. XH NMR (DMSO- d6) δ 8.68 (d, 1H), 8.05 (d, 1H), 8.01 (s, 1H) 7.86 (m, 1H), 7.59 (s, 1H), 7.57 (s, 1H) and 4.09 (s, 3H).
Preparation of 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid (3): A 20 L reactor equipped with a mechanical stirrer, condenser, thermometer, nitrogen inlet and 25% aqueous NaOH trap was charged 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine, 2, (440.6 g, 1.8 mol) and 37% aqueous solution of HQ (5302 g). While being agitated, the reaction solution was heated to 102 °C for 24 hours. Additional 37% aqueous HC1 (2653 g) was added followed by agitation for 18 hours at 104 °C. The reaction contents was then cooled to 5 °C, charged with water (4410 g) and then agitated at 0 °C for 16 hours. The resulting precipitated product was isolated by filtration and washed with water until the filtrate had a pH of 6 (about 8,000 L of water). The filter cake was pulled dry under reduced pressure for 2 hours. The cake was then transferred back into the reactor and triturated in THF (1958 g, 2201 mL) at ambient temperature for 2 hours. The solid product was then isolated by filtration and washed with THF (778 g, 875 mL) and dried under reduced pressure at 5 °C for 48 hours to afford 385 g (89% yield) of the desired product as an off-white solid. HPLC purity was 96.2%. ¾ NMR (DMSO-c/6) δ 8.52 (d, 1H), 7.99 (d, 1H), 7.95 (s, 1H) 7.81 (t, 1H), 7.57 (s, 1H), and 7.55 (s, 1H).
Preparation of methyl { [5 -(3 -chlorophenyl)-3 -hydroxypyridin-2-yl] amino } acetate (4): A 20 L reactor equipped with a mechanical stirrer, condenser, thermometer and nitrogen inlet was charged with 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid, 3, (380 g, 1.52 mol) and diisopropylethylamine (DIPEA)(295 g, 2.28 mol). With agitation, the solution was cooled to 3 °C and charged with trimethylacetyl chloride (275.7 g, 2.29 mol) while maintaining a temperature of less than 1 1 °C, The mixture was then agitated at ambient temperature for 2 hours. The mixture was then cooled to 10 °C and charged with a slurry of glycine methyl ester HC1 (573.3 g, 4. 57 mol) and THF (1689 g, 1900mL), then charged with DIPEA (590.2 g, 4.57 mol) and agitated at ambient temperature for 16 hours. The mixture was then charged with EtOH (1500 g, 1900 mL) and concentrated under reduced pressure to a reaction volume of about 5.8 L. The EtOH addition and concentration was repeated twice more. Water (3800g) was then added and the mixture was agitated for 16 hours at ambient temperature. The resulting solid product was isolated by filtration and washed with a mixture of EtOH (300g, 380 mL) and water (380 g), followed by water (3800g), dried under reduced pressure for 18 hours at 50 °C to afforded 443 g (91% yield) of the desired product as an off-white solid. Purity by HPLC was 98.9%. ¾ NMR (DMSO- d6) δ 12.3 (s, IH), 9.52 (t, IH), 8.56 (d, IH), 7.93 (s, IH), 7.80 (q, 2H), 7.55 (t, 2H), 4.12 (d, 2H), and 3.69 (s, 3H).
Scheme II herein below outlines and Example 2 describes a non-limiting example of the disclosed process for preparing a prolyl hydroxylase inhibitor from an ester prodrug.
Scheme II
Figure imgf000046_0001
4 5
Reagents and conditions: (a) NaOH, THF; 2 hr.
EXAMPLE 3
{ [5 -(3 -Chlorophenyl)-3 -hydroxypyridin-2-yl] amino } acetic acid (5) Preparation of {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}acetic acid (5): To a 50 mL flask is charged methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}- acetate, 4, (0.45 g, 1.4 mmol), tetrahydrofuran (4.5 mL) and 1 M aOH (4.5 mL, 4.5 mmol). The mixture was stirred for 2 hours at room temperature after which it was determined by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components that the reaction was complete. The reaction solution was adjusted to pH 1 with concentrated HC1 and the solution was heated at 35 °C under vacuum until all of the tetrahydrofuran had been removed. A slurry forms as the solution is concentrated. With efficient stirring the pH is adjusted to ~2 with the slow addition of 1 M NaOH. The solid which forms was collected by filtration, washed with water, followed by hexane, then dried under vacuum to afford 0.38 g (88% yield) of the desired product as a white solid. ¾ NMR (DMSO-rfe) δ 12.84 (s, 1H), 12.39 (s, 1H), 9.39 (t, 1H), 8.56 (d, 1H), 7.94 (s, 1H), 7.81 (m, 2H), 7.55 (q, 2H), and 4.02 (d, 2H).
The formulator can readily scale up the above disclosed synthesis. Disclosed herein below is a synthesis wherein the disclosed process is scaled up for commercial use.
EXAMPLE 4
{ [5 -(3 -Chlorophenyl)-3 -hydroxypyridin-2-yl] amino } acetic acid (5)
Preparation of {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}acetic acid (5): To a 20 L reactor equipped with a mechanical stirrer, condenser, thermometer and nitrogen inlet was charged methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}-acetate, 4, (440 g, 1.42 mol), tetrahydrofuran (3912 g, 4400 mL) and 1 M NaOH (4400 mL). The mixture was stirred for 2 hours at room temperature after which it was determined by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize the reaction components that the reaction was complete. The reaction solution was acidified to a pH of 2 with slow addition of 2M HC1 (2359 g). The resulting mixture was concentrated under reduced pressure to a volume of about 7.5 L. Ware (2210 g) was added and the solution cooled to ambient temperature and agitated for 18 hours. The solid product was isolated by filtration and washed with water (6 L). the crude product was transferred back into the reactor and triturated with 2215 g o deionized water at 70 °C for 16 hours. The mixture was cooled to ambient temperature, The solid product was isolated by filtration and washed with water (500 mL) and dried under reduced pressure at 70 °C for 20 hours to afford 368 g (87% yield) of the desired product as an off-white solid. Purity by HPLC was 99.3%. 'H NMR (DMSO-ifc) δ 12.84 (s, 1H), 12.39 (s, 1H), 9.39 (t, 1H), 8.56 (d, 1H), 7.94 (s, 1H), 7.81 (m, 2H), 7.55 (q, 2H), and 4.02 (d, 2H).
Scheme III herein below outlines and Example 3 describes a non-limiting example of the disclosed process for preparing a prolyl hydroxylase amide prodrug.
Scheme III
Figure imgf000048_0001
3 6
Reagents and conditions: (a) EDCI, HOBt, DIPEA, DMF; rt.
EXAMPLE 5
5-(3-Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide Preparation of 5-(3-chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide (6): To a solution of 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid, 3, (749 mg, 3 mmol) in DMF (20 mL) at room temperature under 2 is added l-(3-dimethyl- aminopropyl)-3-ethylcarbodiimide (EDCI) (0.925 g, 5.97 mmol) and 1-hydroxybenzo- triazole (HOBt) (0.806 g, 5.97 mmol). The resulting solution is stirred for 15 minutes then 2-aminoacetamide hydrochloride (0.66 g, 5.97 mmol) and diisopropylethylamine (1.56 ml, 8.96 mmol) are added. The reaction is monitored by TLC and when the reaction is complete the reaction mixture is concentrated under reduced pressure and H20 added. The product can be isolated by normal work-up: The following data have been reported for compound (6). ¾ NMR (250 MHz, DMSO-i/6) δ ppm 12.46 (1 H, s), 9.17 (1 H, t, J= 5.9 Hz), 8.55 (1 H, d, J= 2.0 Hz), 7.93 (1 H, d, J= 0.9 Hz), 7.75 - 7.84 (2 H, m), 7.49 - 7.60 (3 H, m), 7.18 (1 H, s), 3.91 (2 H, d, J= 5.9 Hz). HPLC-MS: m/z 306 [M+H]+.
Scheme IV herein below depicts a non-limiting example the hydrolysis of an amide pro-drug to a prolyl hydroxylase inhibitor after removal of a R10 protecting group.
Scheme IV
Figure imgf000048_0002
Figure imgf000049_0001
While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the disclosure. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this disclosure.

Claims

WHAT IS CLAIMED IS:
1. A compound having the fo
Figure imgf000050_0001
wherein A is a ring chosen from:
i) Ce or Cio aryl; or
ii) C1-C9 heteroaryl;
R10 units represent at least one optionally present substitutions for a ring hydrogen atom; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted Ce or C10 aryl ring, a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
The compound according to Claim 1, wherein A is a C6 aryl ring.
The compound according to either Claim 1 or 2, wherein A is substituted by one or more R10 units independently chosen from:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; ii) C6 or Cio aryl;
iii) C7 or C11 alkylenearyl;
iv) C1-C9 heterocyclic rings;
v) C1-C9 heteroaryl rings;
Figure imgf000050_0002
101
vii) (CRluZaRluZb)aC(0)R
101.
viii) (CR1U2aR1U2 )aC(0)ORl
Figure imgf000050_0003
xiii) halogen;
xiv) -(CR102aR102b)i;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; xvii) -(CR102aR102b)aSR101 ;
xviii) -(CR102aR102b)aSO2R101; and
Figure imgf000051_0001
wherein each R101 is independently hydrogen, substituted or unsubstituted Ci-Ce linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4.
The compound according to any of Claims 1 to 3, wherein A is substituted by more R10 units independently chosen from:
i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl;
ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or
iii) halogen.
5. The compound according to any of Claims 1 to 4, wherein ring A is chosen from 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluoro- phenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3- dichlorophenyl, 3,4-dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromo- phenyl, 3,5-dichlorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6- trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5 -trichlorophenyl, 3,4,5-trichloro- phenyl, and 2,4,6-trichlorophenyl.
6. The compound according to any of Claims 1 to 4, wherein ring A is chosen from 2- chloro-3-methylphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2- chloro-6-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4-methylphenyl, 3- chloro-5-methylphenyl, 3-chloro-6-methyl-phenyl, 2-fluoro-3-methylphenyl, 2- fluoro-4-methylphenyl, 2-fluoro-5-methylphenyl, 2-fluoro-6-methylphenyl, 3- fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl, 3-fluoro-5-methylphenyl, and 3- fluoro-6-methylphenyl.
The compound according to any of Claims 1 to 5, wherein ring A is chosen from 3- chlorophenyl, 3 -fluorophenyl, 3-trifluoromethylphenyl, and 3-chloro-6- methylphenyl.
8. The compound according to Claim 1 , wherein two R10 units are be taken together to form a substituted or unsubstituted C2-C8 heterocyclic ring, wherein the heterocyclic ring comprises one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
The compound according to either Claim 1 or 9, wherein two R10 units are taken together to form an A ring that has a formula chosen from:
Figure imgf000052_0001
A process for preparing a compound having the formula:
Figure imgf000052_0002
wherein R is chosen from:
i) substituted or unsubstituted Ce or C10 aryl; or
ii) substituted or unsubstituted C1-C9 heteroaryl;
L is a linking unit having the formula:
Figure imgf000052_0003
R7a and R7b are each independently:
i) hydrogen; or
ii) Ci-Ce linear, C3-C6 branched or C3-C6 cyclic
R8 is chosen from hydrogen, methyl, or ethyl; and
the index n is an integer from 1 to 4;
or a pharmaceutically acceptable salt thereof, comprising:
A) reacting a boronic acid or ester having the formula:
Y
/
R'-B
Y
wherein Y is OR20, R20 is hydrogen or Ci-Ce linear, C3-C6 branched, or C3- Ce cyclic alkyl, or two OR20 units can be taken together to form a 5 -member to 7-member C3-C10 cyclic ester, with a 3,5-dihalo-2-cyanopyridine having the formula:
Figure imgf000053_0001
each Z is independently chloro or bromo, in the presence of a catalyst, to form a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine having the formula:
Figure imgf000053_0002
B) reacting the 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine formed in step (A) with an alkoxide anion having the formula:
° OR2
wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine having the formula:
Figure imgf000053_0003
reacting the 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine formed (B) with an acid to form a 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine having the formula:
Figure imgf000053_0004
reacting the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine formed step (C) with an amino acid having the formula: I
Ο,Η
H' ^(CR7aR7b),
11. The process according to Claim 10, wherein the boronic acid in step (A) is a
substituted or unsubstituted phenyl boronic acid.
12. The process according to either Claim 10 or 11, wherein the boronic acid in step (A) is a phenyl boronic acid substituted with one or more units independently chosen from:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; ii) C6 or Cio aryl;
iii) C7 or C11 alkylenearyl;
iv) C1-C9 heterocyclic rings;
v) C1-C9 heteroaryl rings;
vi) -(CR102aR102b)aOR101;
vii) -(CR102aR102b)aC(O)R101;
viii) -(CR102aR102b)aC(O)OR101;
ix) -(CR102aR102b)aC(O)N(R101)2;
x) -(CR102aR102b)aN(R101) C(0)R101;
xi) -(CR102aR102b)aN(R101) C(0)2R101;
xii) -(CR102aR102b)aN(R101)2;
xiii) halogen;
xiv) -(CR102aR102b)i;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; xvii) -(CR102aR102b)aSR101;
xviii) -(CR102aR102b)aSO2R101; and
xix) -(CR102aR102b)aSO3R101;
wherein each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; 102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4
13. The process according to any of Claims 10 to 12, wherein the boronic acid in step (A) is substituted by one or more units independently chosen from:
i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl;
ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or
iii) halogen.
14. The process according to any of Claims 10 to 13, wherein the boronic acid in step (A) is chosen from 2-fluorophenylboronic acid, 3-fluorophenylboronic acid, 4- fluorophenylboronic acid, 2-chlorophenylboronic acid, 3-chlorophenylboronic acid, 4-chlorophenylboronic acid, 2-methylphenylboronic acid, 3-methylphenylboronic acid, 4-methylphenylboronic acid, 2-methoxyphenylboronic acid, 3-methoxyphenyl- boronic acid, 4-methoxyphenylboronic acid, 2-cyanophenylboronic acid, 3-cyano- phenylboronic acid, 4-cyanophenylboronic acid, 2-nitrophenylboronic acid, 3-nitro- phenylboronic acid, 4-nitrophenylboronic acid, 2-trifluoromethylphenylboronic acid, 3-trifluoromethylphenylboronic acid, 4-trifluoromethylphenylboronic acid, 2- carbamoylphenylboronic acid, 3-carbamoylphenylboronic acid, 4-carbamoylphenyl- boronic acid, 2-(pyrrolidine- l-carbonyl)phenylboronic acid, 3 -(pyrrolidine- 1- carbonyl)phenylboronic acid, 4-(pyrrolidine- 1 -carbonyl)phenylboronic acid, 2-(cyclopropanecarbonylamino)phenylboronic acid, 3-(cyclopropanecarbonyl- amino)phenylboronic acid, and 4-(cyclopropanecarbonylamino)phenylboronic acid.
15. The process according to any of Claims 10 to 14, wherein the catalyst in step (A) is [ l, l '-bis(diphenyphosphino)ferrocene]dichloro-palladium(II).
16. The process according to any of Claims 10 to 15, wherein the alkoxide in step (B) is methoxide.
17. The process according to any of Claims 10 to 16, wherein the amino acid of step (D) is chosen from glycine, alanine, isoleucine, leucine, valine, 2-amino-2-methyl- propanoic acid, 3-aminobutanoic acid, 3-amino-3-methylbutanoic acid, 3-amino-2- methylbutanoic acid, and 4-aminobutanoic acid.
18. A process for preparing a compound having the formula:
Figure imgf000056_0001
wherein A is a ring chosen from:
i) substituted or unsubstituted Ce or C10 aryl; or
ii) substituted or unsubstituted C1-C9 heteroaryl;
R10 represents one or more independently chosen optionally present substitutions for hydrogen;
X is chosen from:
i) -OH;
ii) -OR3;
iii) -NR4R5; and
iv) -OM1;
R3 is C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl, or benzyl;
R4 and R5 are each independently hydrogen, C1-C12 linear, C3-C12 branched or C3- C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl; benzyl; or R4 and R5 can be taken together with the nitrogen atom to form a 3 to 10 member ring, wherein the ring can optionally contain one or more heteroatoms chosen from oxygen (O), nitrogen (N), or sulfur (S);
M1 is a pharmaceutically acceptable cation;
R7a and R7b are each independently:
i) hydrogen; or
ii) C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl;
R8 is chosen from hydrogen, methyl, or ethyl; and
the index n is an integer from 1 to 4;
or a pharmaceutically acceptable salt thereof,
comprising:
A) reacting a boronic acid or ester having the formula:
Figure imgf000056_0002
wherein Y is OR , R is hydrogen or Ci-C6 linear, C3-C6 branched, or C3- Ce cyclic alkyl, or two OR20 units can be taken together to form a 5 -member to 7-member C3-C10 cyclic ester, with a 3,5-dihalo-2-cyanopyridine having the formula:
Figure imgf000057_0001
each Z is independently chloro or bromo, in the presence of a catalyst, to form a 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine having the formula:
Figure imgf000057_0002
B) reacting the 5-aryl or 5-heteroaryl-3-halo-2-cyanopyridine formed in step (A) with an alkoxide anion having the formula:
Θ
OR
wherein R is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine having the formula:
Figure imgf000057_0003
C) reacting the 5-aryl or 5-heteroaryl-3-alkoxy-2-cyanopyridine formed
(B) with an acid to form a 5-aryl or 5-heteroaryl-3-hydroxy-2- carboxypyridine having the formula:
Figure imgf000057_0004
D) reacting the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine formed in step (C) with a compound having the formula:
Figure imgf000057_0005
19. The process according to Claim 18, wherein the boronic acid in step (A) is a substituted or unsubstituted phenyl boronic acid.
The process according to either Claim 18 or 19, wherein the boronic acid in step (A) is a phenyl boronic acid wherein R10 represents one or more substitutions for hydrogen independently chosen from:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; ii) C6 or Cio aryl;
iii) C7 or C11 alkylenearyl;
iv) C1-C9 heterocyclic rings;
v) C1-C9 heteroaryl rings;
vi) -(CR102aR102b)aOR101;
vii) -(CR102aR102b)aC(O)R101;
viii) -(CR102aR102b)aC(O)OR101;
ix) -(CR102aR102b)aC(O)N(R101)2;
x) -(CR102aR102b)aN(R101) C(0)R101;
xi) -(CR102aR102b)aN(R101) C(0)2R101;
xii) -(CR102aR102b)aN(R101)2;
xiii) halogen;
xiv) -(CR102aR102b)i;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3 ; the index j' is an integer from 0 to 2, j' + k' = 2; xvii) -(CR102aR102b)aSR101;
xviii) -(CR102aR102b)aSO2R101; and
Figure imgf000058_0001
wherein each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3 -7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4
21. The process according to any of Claims 18 to 20, wherein R10 is one or more units independently chosen from: i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl;
ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or
iii) halogen.
22. The process according to any of Claims 18 to 21, wherein the boronic acid in step (A) is chosen from 2-fluorophenylboronic acid, 3-fluorophenylboronic acid, 4- fluorophenylboronic acid, 2-chlorophenylboronic acid, 3-chlorophenylboronic acid, 4-chlorophenylboronic acid, 2-methylphenylboronic acid, 3-methylphenylboronic acid, 4-methylphenylboronic acid, 2-methoxyphenylboronic acid, 3-methoxyphenyl- boronic acid, 4-methoxyphenylboronic acid, 2-cyanophenylboronic acid, 3-cyano- phenylboronic acid, 4-cyanophenylboronic acid, 2-nitrophenylboronic acid, 3-nitro- phenylboronic acid, 4-nitrophenylboronic acid, 2-trifluoromethylphenylboronic acid, 3-trifluoromethylphenylboronic acid, 4-trifluoromethylphenylboronic acid, 2- carbamoylphenylboronic acid, 3-carbamoylphenylboronic acid, 4-carbamoylphenyl- boronic acid, 2-(pyrrolidine-l-carbonyl)phenylboronic acid, 3 -(pyrrolidine- 1- carbonyl)phenylboronic acid, 4-(pyrrolidine- 1 -carbonyl)phenylboronic acid, 2-(cyclopropanecarbonylamino)phenylboronic acid, 3-(cyclopropanecarbonyl- amino)phenylboronic acid, and 4-(cyclopropanecarbonylamino)phenylboronic acid.
23. The process according to any of Claims 18 to 22, wherein the catalyst in step (A) is [l, l '-bis(diphenyphosphino)ferrocene]dichloro-palladium(II).
24. The process according to any of Claims 18 to 23, wherein the compound of step (D) is chosen from glycine, alanine, isoleucine, leucine, valine, 2-amino-2-methyl- propanoic acid, 3-aminobutanoic acid, 3-amino-3-methylbutanoic acid, 3-amino-2- methylbutanoic acid, and 4-aminobutanoic acid.
25. The process according to any of Claims 18 to 23, wherein X is -OR3 or -NR4R5 further comprising the step of hydrolyzing the compound formed in step (D) to form a compound wherein X is -OH.
The process according to Claim 25, wherein the hydrolysis is conducted
presence of an acid catalyst.
27. The process according to Claim 25, wherein the hydrolysis is conducted in the presence of a base catalyst.
28. A compound having the formula:
Figure imgf000060_0001
wherein M is a salt forming cation and N represents the cationic charge on M; A is a ring chosen from:
i) Ce or Cio aryl; or
ii) C1-C9 heteroaryl;
R10 units represent at least one optionally present substitutions for a ring hydrogen atom; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted Ce or Cio aryl ring, a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S). L is a linking unit having the formula:
-(CR7aR7b)n-
R7a and R7b are each independently:
i) hydrogen; or
ii) C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl;
R8 is chosen from hydrogen, methyl, or ethyl; and
the index n is an integer from 1 to 4.
29. The compound according to Claim 28, wherein A is a Ce aryl ring.
30. The compound according to either Claim 28 or 29, wherein A is substituted by one or more R10 units independently chosen from:
i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; ii) C6 or Cio aryl;
iii) C7 or C11 alkylenearyl;
iv) C1-C9 heterocyclic rings; v) C1-C9 heteroaryl rings;
vi) -(CR102aR102b)aOR101;
vii) -(CR102aR102b)aC(O)R101;
viii) -(CR102aR102b)aC(O)OR101;
ix) -(CR102aR102b)aC(O)N(R101)2;
x) -(CR102aR102b)aN(R101) C(0)R101;
xi) -(CR102aR102b)aN(R101) C(0)2R101;
xii) -(CR102aR102b)aN(R101)2;
xiii) halogen;
xiv) -(CR102aR102b)i;
xv) -(CR102aR102b)aNO2;
xvi) -(CHj'Xk')aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j' is an integer from 0 to 2, j' + k' = 2; xvii) -(CR102aR102b)aSR101;
xviii) -(CR102aR102b)aSO2R101; and
Figure imgf000061_0001
wherein each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index "a" is from 0 to 4.
31. The compound according to any of Claims 28 to 30, wherein A is substituted by one or more R10 units independently chosen from:
i) Ci-Ci2 linear, C3-C branched or C3-C cyclic alkyl;
ii) Ci-Ci2 linear, C3-C branched or C3-C cyclic alkoxy; or
iii) halogen.
32. The compound according to any of Claims 28 to 31, wherein ring A is chosen from 2 -fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluoro- phenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3- dichlorophenyl, 3,4-dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromo- phenyl, 3,5-dichlorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6- trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5 -trichlorophenyl, 3,4,5-trichloro- phenyl, and 2,4,6-trichlorophenyl.
33. The compound according to any of Claims 28 to 31, wherein ring A is chosen from
2- chloro-3-methylphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2- chloro-6-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4-methylphenyl, 3- chloro-5-methylphenyl, 3-chloro-6-methyl-phenyl, 2-fluoro-3-methylphenyl, 2- fluoro-4-methylphenyl, 2-fluoro-5-methylphenyl, 2-fluoro-6-methylphenyl, 3- fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl, 3-fluoro-5-methylphenyl, and 3- fluoro-6-methylphenyl.
34. The compound according to any of Claims 28 to 31, wherein ring A is chosen from
3- chlorophenyl, 3 -fluorophenyl, 3-trifluoromethylphenyl, and 3-chloro-6- methylphenyl.
35. The compound according to Claim 28, wherein two R10 units are be taken together to form a substituted or unsubstituted C2-C8 heterocyclic ring, wherein the heterocyclic ring comprises one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
36. The compound according to either Claim 28 or 35, wherein two R10 units are taken together to form an A ring that has a formula chosen from:
Figure imgf000062_0001
PCT/US2012/040833 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides WO2012170377A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
KR1020197007633A KR102032864B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
DK12796374.2T DK2718265T3 (en) 2011-06-06 2012-06-05 Process for the preparation of [(3-Hydroxypyridine-2-carbonyl) amino] alkanoic acids, esters and amides
KR1020147000297A KR102000485B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
KR1020207029586A KR102293016B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CA2838194A CA2838194C (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CN201280038564.3A CN103717575B (en) 2011-06-06 2012-06-05 For preparing [(3-pyridone-2-carbonyl) amino] alkanoic acid, ester and the method for amide
KR1020197037296A KR102171315B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
EP19214405.3A EP3683209B1 (en) 2011-06-06 2012-06-05 Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
EP21206374.7A EP4026829A1 (en) 2011-06-06 2012-06-05 Process for preparing n-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-glycine from 5-(3-chlorophenyl)-3-hydroxy-2-pyridine carboxylic acid
PL19214405T PL3683209T3 (en) 2011-06-06 2012-06-05 Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
CN201610967348.7A CN106518759B (en) 2011-06-06 2012-06-05 The method for being used to prepare [(3- pyridone -2- carbonyl) amino] alkanoic acid, ester and amide
ES12796374.2T ES2559850T3 (en) 2011-06-06 2012-06-05 Process for preparing acids, esters and amides [(3-hydroxypyridin-2-carbonyl) amino] alkanoic acids
AU2012268426A AU2012268426B2 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
SI201230432T SI2718265T1 (en) 2011-06-06 2012-06-05 Process for preparing ((3-hydroxypyridine-2-carbonyl)amino)alkanoic acids, esters and amides
RS20160013A RS54517B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
PL17191362T PL3290404T3 (en) 2011-06-06 2012-06-05 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives as intermediates in the preparation of [(5-(halophenyl)-3-hydroxypyridine-2-carbonyl)-amino]alkanoic acid derivatives
KR1020197007630A KR102059366B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
RU2013158640/04A RU2602083C2 (en) 2011-06-06 2012-06-05 Method of producing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
NZ618570A NZ618570B2 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
EP12796374.2A EP2718265B1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
PL12796374T PL2718265T3 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
MX2013014228A MX337216B (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkano ic acids, esters and amides.
MX2015016579A MX347709B (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkano ic acids, esters and amides.
JP2014514536A JP6290781B2 (en) 2011-06-06 2012-06-05 [(3-Hydroxypyridine-2-carbonyl) amino] alkanoic acid, ester and amide production method
EP17191362.7A EP3290404B1 (en) 2011-06-06 2012-06-05 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives as intermediates in the preparation of [(5-(halophenyl)-3-hydroxypyridine-2-carbonyl)-amino]alkanoic acid derivatives
IL229775A IL229775A (en) 2011-06-06 2013-12-03 Process for preparing [(3-hydroxypyridine-2 - carbonyl) amino] alkanoic acids, esters and amides
HK14110125.1A HK1196616A1 (en) 2011-06-06 2014-10-10 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides [(3--2-)]
HRP20151416T HRP20151416T1 (en) 2011-06-06 2015-12-23 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
SM201600013T SMT201600013B (en) 2011-06-06 2016-01-15 PROCEDURE FOR THE PREPARATION OF ACIDS, ESTERS, AND AMMIDS [(3-HYDROXYPYLIDIN-2-CARBONYL) AMINO] ALCANOANIC
AU2017202414A AU2017202414B2 (en) 2011-06-06 2017-04-12 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
AU2018250355A AU2018250355B2 (en) 2011-06-06 2018-10-15 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CY20201100087T CY1122639T1 (en) 2011-06-06 2020-02-03 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF [(5-HALOPHENYL)-3-HYDROXYPYRIDINO-2-CARBONYL)- AMINO]ALKANOIC ACID DERIVATIVES
AU2020204528A AU2020204528B2 (en) 2011-06-06 2020-07-07 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
CY20211101079T CY1124874T1 (en) 2011-06-06 2021-12-08 PROCESS FOR THE PREPARATION OF [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINO-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR THE PREPARATION OF 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06
US61/493,536 2011-06-06

Publications (1)

Publication Number Publication Date
WO2012170377A1 true WO2012170377A1 (en) 2012-12-13

Family

ID=47262177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/040833 WO2012170377A1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Country Status (24)

Country Link
US (6) US9145366B2 (en)
EP (5) EP3290404B1 (en)
JP (6) JP6290781B2 (en)
KR (5) KR102171315B1 (en)
CN (1) CN106518759B (en)
AU (4) AU2012268426B2 (en)
CA (2) CA3135440A1 (en)
CY (4) CY1117177T1 (en)
DK (4) DK2718265T3 (en)
ES (4) ES2559850T3 (en)
HK (3) HK1196616A1 (en)
HR (4) HRP20211916T1 (en)
HU (4) HUE026096T2 (en)
IL (1) IL229775A (en)
LT (3) LT3000808T (en)
MX (2) MX337216B (en)
NO (1) NO2686520T3 (en)
PL (4) PL2718265T3 (en)
PT (4) PT3000808T (en)
RS (3) RS54517B1 (en)
RU (2) RU2602083C2 (en)
SI (4) SI3683209T1 (en)
SM (1) SMT201600013B (en)
WO (1) WO2012170377A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701636B2 (en) 2013-11-15 2017-07-11 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2018108101A1 (en) * 2016-12-13 2018-06-21 苏州科睿思制药有限公司 New crystal forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and preparation method therefor
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US10246416B2 (en) 2011-06-06 2019-04-02 Akebia Therapeutics, Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US10729681B2 (en) 2006-06-26 2020-08-04 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
WO2022006427A1 (en) 2020-07-02 2022-01-06 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
WO2022018450A1 (en) * 2020-07-23 2022-01-27 Johnson Matthey Public Limited Company Crystalline forms of vadadustat and methods for their preparation
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11857543B2 (en) 2013-06-13 2024-01-02 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
EP3270922A4 (en) * 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (en) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3- hydroxypyridine compound, preparation method and its pharmaceutical applications
EP3600274A1 (en) * 2017-03-29 2020-02-05 Emerald Health Pharmaceuticals Inc. Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions for use in methods of treatment of hemoglobin disorders
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020217733A1 (en) * 2019-04-26 2020-10-29 株式会社カネカ Method for producing vadadustat intermediate
CN111087343B (en) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 Hydroxypyridine ligand, preparation method and catalytic application thereof
US20230159462A1 (en) * 2019-12-10 2023-05-25 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
JPWO2021149724A1 (en) 2020-01-24 2021-07-29
WO2023111990A1 (en) 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
WO2009111133A1 (en) * 2008-03-04 2009-09-11 General Electric Company System and method of morphology feature analysis of physiological data
US20100021423A1 (en) * 2008-07-23 2010-01-28 Roche Palo Alto Llc Heterocyclic antiviral compounds

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (en) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (en) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation
DK0650961T3 (en) 1993-11-02 1997-09-15 Hoechst Ag Substituted heterocyclic carboxylic acid amides, their preparation and their use as drugs.
ATE149485T1 (en) 1993-11-02 1997-03-15 Hoechst Ag SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carboxamides and their pyridine N-oxides, processes for their preparation and their use as medicaments
DE4410480A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridine-2-carboxylic acid ester amides and their pyridine N-oxides, processes for their preparation and their use as medicaments
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
JPH09221476A (en) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd Medicinal composition
JP2000509047A (en) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト 3-Alkoxypyridine-2-carboxamide esters, their preparation and their use as medicaments
DE19620041A1 (en) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
DE19650215A1 (en) 1996-12-04 1998-06-10 Hoechst Ag 3-hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
EP1080075B1 (en) 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperididinyl and n-amidinopiperidinyl derivatives
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (en) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd Tricyclic heteroaryl derivative
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
JP4590157B2 (en) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド Assays, methods and means
SE0101327D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
CA2486141A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
RU2005108667A (en) 2002-08-29 2005-08-27 Мерк энд Ко., Инк. (US) N-BIARILMETHYLAMINOCYCLOCALACANBOXAMIDE DERIVATIVES
PL376770A1 (en) 2002-10-16 2006-01-09 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
WO2004048383A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN102977016B (en) 2003-06-06 2015-01-14 菲布罗根有限公司 Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005108370A1 (en) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Benzene compounds
NZ551632A (en) 2004-05-28 2009-09-25 Fibrogen Inc HIF prolyl hydroxylase activity assay
WO2005115984A2 (en) 2004-05-31 2005-12-08 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activitated k channel opener
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
KR20080028918A (en) 2005-06-15 2008-04-02 피브로겐, 인크. Compounds and methods for treatment of cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
JP5202327B2 (en) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド Quinolone-based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions thereof and uses thereof
EP1971618A2 (en) 2006-01-09 2008-09-24 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP2009523812A (en) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Fusion heterobicyclic kinase inhibitors
JP4801451B2 (en) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ Control device and control method for electron gun used in scanning electron microscope and the like
ITMI20060179A1 (en) 2006-02-02 2007-08-03 Abiogen Pharma Spa PROCEDURE FOR RESOLUTION OF RACEMIC MIXTURES AND DIASTEREOISOMERIC COMPLEX OF A SOLVING AGENT AND UNANTIOMER OF INTEREST
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (en) 2006-03-07 2008-04-23 Smithkline Beecham Corp COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl Hydroxylase Inhibitors
CL2008000066A1 (en) 2007-01-12 2008-08-01 Smithkline Beecham Corp COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM
CL2008000065A1 (en) 2007-01-12 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA.
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
AU2008254270B2 (en) 2007-05-16 2013-06-06 Merck Sharp & Dohme Corp. Spiroindalones
CN101765596B (en) 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8268794B2 (en) 2007-08-06 2012-09-18 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (en) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 Pyridine derivate and using method thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
CN101983384A (en) 2007-11-30 2011-03-02 葛兰素史密斯克莱有限责任公司 Prolyl hydroxylase inhibitors
JP2011505367A (en) 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Prolyl hydroxylase inhibitor
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
CN102015651B (en) * 2008-03-03 2014-12-31 Irm责任有限公司 Compounds and compositions as TLR activity modulators
AU2009225441B2 (en) * 2008-03-20 2012-12-13 Forest Laboratories Holdings Limited Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase
AR071997A1 (en) 2008-06-04 2010-07-28 Bristol Myers Squibb Co CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
NZ591394A (en) 2008-09-15 2013-03-28 Kasina Laila Innova Pharmaceuticals Private Ltd Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
EP2370422B1 (en) 2008-11-14 2019-06-05 Fibrogen, Inc. Thiochromene derivatives as hif hydroxylase inhibitors
JP5638513B2 (en) * 2009-03-31 2014-12-10 キッセイ薬品工業株式会社 Indolizine derivatives and their pharmaceutical use
MX2012005273A (en) 2009-11-06 2012-06-19 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha.
EP2717870B1 (en) * 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
NO2686520T3 (en) 2011-06-06 2018-03-17
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
ES2606631T3 (en) 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Polymeric forms of compounds as a prolyl hydroxylase inhibitor, and uses thereof
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
NZ753904A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP3032953A4 (en) 2013-08-16 2017-02-08 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
RU2021125455A (en) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. SOLID FORMS {[5- (3-CHLOROPHENYL) -3-HYDROXYPIRIDINE-2-CARBONYL] AMINO} ACETIC ACID, THEIR COMPOSITIONS AND APPLICATIONS
MX2016009331A (en) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Compositions and methods for treating ocular diseases.
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
LT3277270T (en) 2015-04-01 2022-01-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
MX2020011845A (en) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino]acetic acid.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
WO2009111133A1 (en) * 2008-03-04 2009-09-11 General Electric Company System and method of morphology feature analysis of physiological data
US20100021423A1 (en) * 2008-07-23 2010-01-28 Roche Palo Alto Llc Heterocyclic antiviral compounds

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883386B2 (en) 2006-06-26 2024-01-30 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
US10729681B2 (en) 2006-06-26 2020-08-04 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
US11426393B2 (en) 2006-06-26 2022-08-30 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
US11267785B2 (en) 2011-06-06 2022-03-08 Akebia Therapeutics, Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
US10738010B2 (en) 2011-06-06 2020-08-11 Akebia Therapeutics, Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
US10246416B2 (en) 2011-06-06 2019-04-02 Akebia Therapeutics, Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
US11857543B2 (en) 2013-06-13 2024-01-02 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US10596158B2 (en) 2013-11-15 2020-03-24 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US11690836B2 (en) 2013-11-15 2023-07-04 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10149842B2 (en) 2013-11-15 2018-12-11 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US9987262B2 (en) 2013-11-15 2018-06-05 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
JP2020183408A (en) * 2013-11-15 2020-11-12 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US11065237B2 (en) 2013-11-15 2021-07-20 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US9701636B2 (en) 2013-11-15 2017-07-11 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11844756B2 (en) 2015-04-01 2023-12-19 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN110088088B (en) * 2016-12-13 2022-03-29 苏州科睿思制药有限公司 Novel crystal form of { [5- (3-chlorphenyl) -3-hydroxypyridine-2-carbonyl ] amino } acetic acid and preparation method thereof
US10703724B2 (en) 2016-12-13 2020-07-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
CN110088088A (en) * 2016-12-13 2019-08-02 苏州科睿思制药有限公司 The novel crystal forms and preparation method thereof of { [5- (3- chlorphenyl) -3- pyridone -2- carbonyl] amino } acetic acid
WO2018108101A1 (en) * 2016-12-13 2018-06-21 苏州科睿思制药有限公司 New crystal forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and preparation method therefor
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2022006427A1 (en) 2020-07-02 2022-01-06 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
WO2022018450A1 (en) * 2020-07-23 2022-01-27 Johnson Matthey Public Limited Company Crystalline forms of vadadustat and methods for their preparation

Also Published As

Publication number Publication date
KR102032864B1 (en) 2019-10-16
CN106518759A (en) 2017-03-22
EP2718265B1 (en) 2015-12-16
HRP20151416T1 (en) 2016-03-25
CA2838194C (en) 2022-01-11
SI3000808T1 (en) 2018-02-28
EP3000808A1 (en) 2016-03-30
JP7039682B2 (en) 2022-03-22
NO2686520T3 (en) 2018-03-17
SI2718265T1 (en) 2016-03-31
CA3135440A1 (en) 2012-12-13
US10738010B2 (en) 2020-08-11
ES2771232T3 (en) 2020-07-06
RU2016139352A3 (en) 2020-01-27
JP6510094B2 (en) 2019-05-08
AU2018250355B2 (en) 2020-04-09
AU2018250355A1 (en) 2018-11-08
EP3290404A1 (en) 2018-03-07
AU2017202414B2 (en) 2018-07-19
SI3683209T1 (en) 2022-03-31
KR20190031593A (en) 2019-03-26
HK1252109A1 (en) 2019-05-17
US20190375713A1 (en) 2019-12-12
RU2013158640A (en) 2015-07-20
EP4026829A1 (en) 2022-07-13
KR102000485B1 (en) 2019-07-16
HRP20171740T1 (en) 2018-03-09
CN106518759B (en) 2019-07-30
JP2018111697A (en) 2018-07-19
DK3290404T3 (en) 2020-02-17
HUE034975T2 (en) 2018-05-02
PL3683209T3 (en) 2022-02-21
PL3290404T3 (en) 2020-06-01
RS56580B1 (en) 2018-02-28
AU2020204528A1 (en) 2020-07-30
PL2718265T3 (en) 2016-04-29
EP3683209A1 (en) 2020-07-22
RU2602083C2 (en) 2016-11-10
ES2647602T3 (en) 2017-12-22
HK1216173A1 (en) 2016-10-21
MX347709B (en) 2017-05-10
EP3290404B1 (en) 2019-12-11
AU2020204528B2 (en) 2022-07-14
EP2718265A1 (en) 2014-04-16
KR102293016B1 (en) 2021-08-26
HUE048044T2 (en) 2020-05-28
JP6290781B2 (en) 2018-03-07
KR20140037192A (en) 2014-03-26
IL229775A (en) 2016-06-30
CY1117177T1 (en) 2017-04-05
DK3683209T3 (en) 2021-12-06
AU2012268426A1 (en) 2014-01-09
HRP20200197T1 (en) 2020-05-15
JP2021059573A (en) 2021-04-15
EP3000808B1 (en) 2017-09-27
PT2718265E (en) 2016-02-15
JP2023103414A (en) 2023-07-26
DK2718265T3 (en) 2016-01-25
RS54517B1 (en) 2016-06-30
US20170362178A1 (en) 2017-12-21
RS59902B1 (en) 2020-03-31
US9145366B2 (en) 2015-09-29
HRP20211916T1 (en) 2022-03-18
HUE026096T2 (en) 2016-05-30
PT3000808T (en) 2017-11-23
HUE057571T2 (en) 2022-05-28
KR20200121911A (en) 2020-10-26
AU2017202414A1 (en) 2017-05-04
KR102059366B1 (en) 2019-12-26
CA2838194A1 (en) 2012-12-13
PT3683209T (en) 2021-12-15
SMT201600013B (en) 2016-02-25
ES2900572T3 (en) 2022-03-17
JP2019123741A (en) 2019-07-25
JP6816195B2 (en) 2021-01-20
PT3290404T (en) 2020-02-19
CY1122639T1 (en) 2021-03-12
KR20190141805A (en) 2019-12-24
RU2016139352A (en) 2018-12-13
US20150361043A1 (en) 2015-12-17
KR102171315B1 (en) 2020-10-28
NZ618570A (en) 2015-07-31
CY1124874T1 (en) 2022-11-25
MX337216B (en) 2016-02-18
MX2013014228A (en) 2014-03-26
US20120309977A1 (en) 2012-12-06
SI3290404T1 (en) 2020-03-31
ES2559850T3 (en) 2016-02-16
KR20190032617A (en) 2019-03-27
US11267785B2 (en) 2022-03-08
US20230002323A1 (en) 2023-01-05
HK1196616A1 (en) 2014-12-19
LT3000808T (en) 2018-01-25
EP3683209B1 (en) 2021-11-10
LT3290404T (en) 2020-02-25
CY1119605T1 (en) 2018-04-04
DK3000808T3 (en) 2017-11-27
PL3000808T3 (en) 2018-03-30
CN103717575A (en) 2014-04-09
EP2718265A4 (en) 2014-11-19
JP2014522409A (en) 2014-09-04
RU2764667C2 (en) 2022-01-19
US10246416B2 (en) 2019-04-02
US20210122715A1 (en) 2021-04-29
JP2022081597A (en) 2022-05-31
JP7284309B2 (en) 2023-05-30
LT3683209T (en) 2022-01-10
AU2012268426B2 (en) 2017-02-16
US9776969B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
AU2017202414B2 (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796374

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2838194

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/014228

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014514536

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012796374

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147000297

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012268426

Country of ref document: AU

Date of ref document: 20120605

Kind code of ref document: A

Ref document number: 2013158640

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-2016/0013

Country of ref document: RS